

CITATION REPORT

List of articles citing

Proposals for the classification of the myelodysplastic syndromes

DOI: 10.1111/j.1365-2141.1982.tb02771.x

British Journal of Haematology, 1982, 51, 189-199.

Source: <https://exaly.com/paper-pdf/16003528/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2213	The diagnosis of preleukaemia. <i>British Journal of Haematology</i> , 1983 , 55, 1-6	4.5	16
2212	Refractory anaemia with excess of blasts in transformation: is a new category necessary?. <i>British Journal of Haematology</i> , 1983 , 55, 196-7	4.5	4
2211	Flow cytometric DNA content in myelodysplastic syndromes. 1983 , 4, 238-43		26
2210	Use of bone-marrow culture in prediction of acute leukaemic transformation in preleukaemia. 1983 , 1, 1409-12		41
2209	Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. 1983 , 36, 566-9		35
2208	Dr Juneja and colleagues reply as follows. 1983 , 36, 1414-1414		
2207	Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. 1983 , 36, 1129-35		60
2206	Ring sideroblasts and myelodysplastic syndromes. 1983 , 36, 1413-4		1
2205	Smoldering Acute Granulocytic Leukemia. 1983 , 143, 37		17
2204	Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. 1983 , 36, 1120-8		57
2203	Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia. 1983 , 79, 525-30		23
2202	Auer rods in refractory anemia with excess of blasts: presence and significance. 1983 , 80, 359-62		12
2201	Leukemia following treatment of germ cell tumors in men. 1984 , 2, 1080-7		80
2200	Chapter 1. Chemotherapy and prognosis of acute nonlymphocytic leukaemia in adults. A review of the literature. 1984 , 1-12		
2199	Allogeneic marrow transplantation in the treatment of preleukemia. 1984 , 100, 689-93		71
2198	Granulocytic Sarcoma. 1984 , 120, 1341		17
2197	The effect of low dose Ara-C in acute nonlymphoblastic leukaemias and atypical leukaemia. <i>British Journal of Haematology</i> , 1984 , 58, 9-18	4.5	42

2196	A reliable method with good cell preservation for the demonstration of peroxidase activity in human platelets and megakaryocytes. 1984 , 80, 79-84		4
2195	Cytarabine in pre-leukaemia. 1984 , 1, 1187		10
2194	Treatment of advanced myelodysplastic syndrome with alfacalcidol. 1984 , 2, 761		35
2193	How potent is the inhibition of drug metabolism by omeprazole?. 1984 , 2, 761		7
2192	Dysmyelopoietic syndrome. Current concepts. 1984 , 76, 122-8		15
2191	Associated abnormalities of chromosomes 1, 5, and 11 in dysmyelopoietic syndromes. 1984 , 12, 31-7		9
2190	Chromosome analysis of 63 cases of secondary nonlymphoid blood disorders: a cooperative study. Groupe Francais de Cytog ⁿ n ⁿ tique H ⁿ matologique. 1984 , 12, 95-104		86
2189	Empyema of the gallbladder. 1984 , 1, 1187		1
2188	Blood levels and in vitro activity of desethylchloroquine against Plasmodium falciparum. 1984 , 1, 1186-7		16
2187	A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). 1984 , 81, 733-41		55
2186	Myelodysplastic syndromes in children: Observations on five cases. 1984 , 1, 71-75		6
2185	Acute lymphoblastic leukemia following myelodysplastic syndrome. 1985 , 84, 233-7		16
2184	Preleukemia/Dysmyelopoietic Syndrome. 1985 , 16, 157-163		5
2183	Low dose cytarabine in acute non-lymphoblastic leukemia or myelodysplastic syndrome: report of six cases and review of the literature. 1985 , 15, 10-5		7
2182	Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. <i>British Journal of Haematology</i> , 1985 , 60, 19-32	4.5	182
2181	Myelodysplastic syndromes in childhood: three case reports. <i>British Journal of Haematology</i> , 1985 , 60, 137-42	4.5	18
2180	Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system. <i>Hematological Oncology</i> , 1985 , 3, 55-63	1.3	101
2179	Chronic myelomonocytic leukemia: clinical features, cytogenetics, and prognosis in 30 consecutive cases. <i>Hematological Oncology</i> , 1985 , 3, 147-55	1.3	25

2178	Increased numbers of marrow basophils may be associated with a t(6;9) in ANLL. <i>American Journal of Hematology</i> , 1985 , 18, 393-403	7.1	92
2177	Danazol therapy in myelodysplasia. 1985 , 103, 58-60		45
2176	Report of the Committee on Chromosome Rearrangements in Neoplasia and on Fragile Sites. 1985 , 40, 490-535		186
2175	Management of myelodysplastic syndromes. 1985 , 103, 136-8		11
2174	Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience. 1985 , 3, 1640-58		174
2173	FAB M7: acute megakaryoblastic leukemia--beyond morphology. 1985 , 103, 450-2		18
2172	Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. 1985 , 3, 982-91		61
2171	Leukaemia after cervical cancer irradiation in Denmark. 1985 , 14, 363-8		10
2170	Immune abnormalities in myelodysplastic syndromes. 1985 , 38, 908-11		46
2169	Opsonophagocytosis of group B streptococci: the role of sialic acid. 1985 , 38, 114-5		
2168	Refractory anaemia terminating in a combined lymphoproliferative and myeloproliferative disorder. 1985 , 38, 297-300		13
2167	Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features. 1985 , 38, 1218-24		86
2166	Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications. 1985 , 38, 1201-17		90
2165	Erythrocyte ferritin concentration in patients with myelodysplastic syndromes. 1985 , 38, 113-4		6
2164	Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. 1985 , 103, 620-5		1894
2163	Progenitor cells and classification of myelodysplastic and myeloproliferative disorders. 1985 , 2, 885		4
2162	Specific cutaneous involvement in the course of chronic myelomonocytic leukemia simultaneously with blastic leukemic transformation. Report of a case with histologic and cytochemical study. 1985 , 12, 943-8		15
2161	Galba Araujo of Brazil and episiotomy. 1985 , 2, 884-5		

2160	Two distinct toxins active on Vero cells from Escherichia coli O157. 1985 , 2, 885-6	147
2159	Karyotypic evolution in patients with myelodysplastic syndromes. 1985 , 16, 157-67	55
2158	Loss of the Y chromosome in acute myelogenous leukemia: a report of 13 patients. 1985 , 17, 269-78	51
2157	Involvement of chromosomes 4, 11, and 17 in a case of myelodysplastic syndrome. 1985 , 18, 265-73	7
2156	A 2p;11q chromosome translocation in dysmyelopoietic preleukemia. 1985 , 15, 143-50	23
2155	Increased sister chromatid exchange frequency in bone marrow cells of myelodysplastic syndromes. 1985 , 15, 151-8	3
2154	Acute myeloblastic leukaemia in a dog. 1985 , 95, 619-32	11
2153	PROGNOSIS IN MYELOYDYSPLASIA. 1986 , 328, 436-437	
2152	Britain Needs a Food and Health Policy: the Government Must Face its Duty. 1986 , 328, 434-436	
2151	Coexistence of S ⁺ zary syndrome and dysmyelopoiesis with an excess of myeloblasts. 1986 , 15, 1296-8	4
2150	The histological characterization of ALIP in the myelodysplastic syndromes. 1986 , 181, 402-7	13
2149	Cytogenetic studies in 18 patients with secondary blood disorders. 1986 , 22, 309-17	13
2148	Three cases of preleukemic myelodysplastic disorders with the same translocation t(1;3). 1986 , 19, 213-8	19
2147	Abnormalities of the short arm of chromosome 12 in acute nonlymphocytic leukemia and dysmyelopoietic syndrome. 1986 , 19, 281-9	50
2146	Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes. 1986 , 23, 61-75	51
2145	Another case of myelodysplastic syndrome with a chromosome mode in the tetraploid range. 1986 , 23, 175-8	4
2144	Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. 1986 , 105, 673-9	53
2143	A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. 1986 , 4, 1857-64	179

2142	Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. 1986 , 4, 1748-57		216
2141	Low-dose cytosine arabinoside in myelodysplastic syndromes. 1986 , 41, 83-8		1
2140	A variant myelodysplastic syndrome with multilineage Pelgeroid chromatin. 1986 , 85, 176-9		8
2139	Ph1-negative chronic granulocytic leukemia: a nonentity. 1986 , 85, 186-93		68
2138	Myelodysplasia progressing to acute myeloblastic leukemia in an HTLV-III virus-positive homosexual man with AIDS-related complex. 1986 , 86, 788-91		38
2137	Basophilia as a feature of the myelodysplastic syndrome. 1986 , 8, 269-71		4
2136	Response of refractory anemia to low-dose cytosine arabinoside. 1986 , 16, 231-3		1
2135	Marrow Transplantation in Preleukemia. 1986 ,		
2134	Chromosomes in acute nonlymphocytic leukemia. 1986 , 73, 137-46		62
2133	Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. 1986 , 52, 35-43		7
2132	Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia. 1986 , 53, 423-36		25
2131	The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia. 1986 , 52, 357-63		15
2130	Cytogenetic evidence for partially committed myeloid progenitor cell origin of chronic myelomonocytic leukaemia and juvenile chronic myeloid leukaemia: both granulocyte-macrophage precursors and erythroid precursors carry identical marker chromosome. <i>British Journal of Haematology</i> , 1986 , 64, 539-46	4.5	42
2129	Increased alpha:non-alpha globin chain synthesis ratios in myelodysplastic syndromes and myeloid leukaemia. 1986 , 39, 1233-5		10
2128	Primary myelodysplastic syndrome with complex chromosomal rearrangements in a patient with Klinefelter's syndrome. 1986 , 23, 183-5		6
2127	Myelodysplastic syndrome coexisting with acute lymphoblastic leukaemia. 1986 , 39, 728-30		13
2126	Chemotherapy-Induced Complete Remission of a Malignant Fibrous Histiocytoma of Bone. 1986 , 146, 786		2
2125	Preleukemia Manifested by Hemolytic Anemia With Pyruvate-Kinase Deficiency. 1986 , 146, 785		2

2124	Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid. 1987 , 40, 652-6	19
2123	Circulating micromegakaryocytes in myelodysplasia. 1987 , 40, 1349-52	26
2122	Identification of neutrophils with an oxazine dye. 1987 , 88, 436-41	5
2121	Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. 1987 , 87, 180-6	76
2120	RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. 1987 , 84, 9228-32	178
2119	Isodicentric X chromosome in a patient with myelodysplastic syndrome. 1987 , 27, 215-8	9
2118	Cytogenetic findings in siblings with a myelodysplastic syndrome. 1987 , 27, 241-9	8
2117	Leukemic transformation in patients with the 5q- alteration: analysis of the behavior of the 5q- clones in preleukemic to leukemic phases. 1987 , 26, 199-207	12
2116	Translocation (1;7) in a case of secondary chronic myelomonocytic leukemia. 1987 , 24, 355-7	12
2115	Refractory anemia with monosomy 2 and a double minute chromosome. 1987 , 28, 367-71	3
2114	11q-chromosome is associated with abnormal iron stores in myelodysplastic syndromes. 1987 , 27, 39-44	40
2113	Absence of diabetes in a rural West African population with a high carbohydrate/cassava diet. 1987 , 1, 765-8	61
2112	Cytochemical characterization of leukemic cells with numerous cytoplasmic granules. 1987 , 62, 978-85	9
2111	Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. 1987 , 1, 763-5	61
2110	Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. 1987 , 1, 135-7	175
2109	Malignant melanoma in the elderly. 1987 , 5, 1129	3
2108	Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. 1987 , 5, 1822-6	69
2107	The myelodysplastic syndromes. 1987 , 295, 227-8	4

2106	Refractory cytopenias: clinical course according to bone marrow cytology and cellularity. 1987 , 54, 153-63		18
2105	Allogeneic bone marrow transplantation as primary therapy for chronic myelomonocytic leukemia. 1987 , 54, 189-92		2
2104	Leukocyte-derived inhibitory activity in patients with myelodysplastic syndrome. 1987 , 55, 165-71		4
2103	In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity. 1987 , 54, 299-306		
2102	Histopathology of bone marrow in human immunodeficiency virus infection. 1987 , 411, 543-51		50
2101	The prognostic significance of cytological, histological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. A follow up study. 1987 , 54, 231-8		5
2100	The myelodysplastic syndrome--a practical guide. <i>Hematological Oncology</i> , 1987 , 5, 19-34	1.3	55
2099	The myelodysplastic syndromes. 1987 , 1, 34-43		22
2098	Haem arginate as a treatment for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1987 , 65, 425-8	4.5	23
2097	Myelodysplastic syndromes. 1987 , 1, 389-426		42
2096	Haematological classification of the chronic myeloid leukaemias. 1987 , 1, 887-906		45
2095	Chromosome abnormalities in CML. 1987 , 1, 963-81		23
2094	The syndrome of abnormal chromatin clumping in leucocytes: a myelodysplastic disorder with proliferative features?. <i>British Journal of Haematology</i> , 1988 , 70, 49-54	4.5	47
2093	An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1988 , 68, 97-101	4.5	33
2092	Enrichment of haemopoietic progenitor cells from the marrow of patients with myelodysplasia. <i>British Journal of Haematology</i> , 1988 , 68, 159-64	4.5	7
2091	Childhood monosomy 7 revisited. <i>British Journal of Haematology</i> , 1988 , 69, 41-5	4.5	43
2090	Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. 1988 , 18, 512-6		93
2089	Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside. <i>American Journal of Hematology</i> , 1988 , 29, 79-84	7.1	7

2088	Treatment of myelodysplastic syndromes with low-dose oral 6-thioguanine. 1988 , 16, 17-20		6
2087	Hematologic and clinical features of patients with chromosome 5 monosomy or deletion (5q). 1988 , 16, 88-94		17
2086	Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. <i>Hematological Oncology</i> , 1988 , 6, 299-305	1.3	15
2085	Chronic myelomonocytic leukemia and primary Sjögren's syndrome. 1988 , 7, 110-3		5
2084	Secondary leukemia after severe aplastic anemia. 1988 , 56, 79-81		7
2083	Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes. 1988 , 57, 45-9		19
2082	Clinicopathological study of hematological disorders after Thorotrast administration in Japan. 1988 , 56, 153-60		6
2081	Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation. 1988 , 57, 357-60		2
2080	Sweet's syndrome and myelodysplasia. 1988 , 56, 47-8		13
2079	Chromosome study of 85 patients with myelodysplastic syndrome. 1988 , 33, 39-50		60
2078	Translocation t(1;7) revisited. Report of three further cases and review. 1988 , 36, 45-54		18
2077	Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias. 1988 , 30, 1-15		109
2076	Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22 [corrected] and t(1;7)(q21;q11). 1988 , 30, 83-90		11
2075	Myelodysplastic syndrome with Philadelphia-like chromosome without bcr rearrangement. 1988 , 35, 151-8		5
2074	Cytogenetic findings in leukemic cells of 56 patients with constitutional chromosome abnormalities. A cooperative study. Groupe Français de Cytog ⁿ n ^e tique H ⁿ matologique. 1988 , 35, 243-52		38
2073	An identical t(Y;1)(q12;q21) in two patients with myelodysplastic syndromes. 1988 , 34, 285-93		21
2072	Systemic treatment of cancer in the elderly. 1988 , 7, 119-50		19
2071	Therapeutic efficacy of danazol in myelodysplastic syndromes. 1988 , 24, 1481-9		16

2070	Ringed Sideroblasts in Primary Myelodysplasia. 1988 , 148, 653	5
2069	Granulocytic sarcomas of the head and neck. 1988 , 114, 1467-70	18
2068	Diagnostic and prognostic value of DNA image cytometry in myelodysplasia. 1988 , 41, 604-8	8
2067	Refractory myelodysplastic anaemias with hypocellular bone marrow. 1988 , 41, 763-7	41
2066	Reclassification of Leukemia among A-Bomb Survivors in Nagasaki Using French-American-British (FAB) Classification for Acute Leukemia. 1988 ,	
2065	The Philadelphia chromosome: a brief review. 1988 , 18, 617-23	1
2064	Preleukemic syndromes and other syndromes predisposing to leukemia. 1988 , 35, 853-71	9
2063	Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. 1988 , 6, 1417-24	97
2062	Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. 1988 , 6, 1851-5	30
2061	Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. 1989 , 7, 629-37	159
2060	Myelodysplastic syndrome preceding acute myelomonocytic leukemia with dysplastic marrow eosinophilia and inv(16). 1989 , 82, 161-4	16
2059	A case of chronic neutrophilic leukemia with trisomy 8. 1989 , 81, 148-51	28
2058	Myelodysplastic syndrome: prospective evaluation of fifty-one patients using the Dutcher scoring system. 1989 , 81, 86-90	8
2057	Lymphoid blast crisis in a patient with Philadelphia-chromosome-negative chronic myelocytic leukemia. 1989 , 81, 155-9	2
2056	Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study. 1989 , 12, 13-5	10
2055	Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. 1989 , 7, 1637-45	110
2054	Primary acquired sideroblastic erythropoiesis in non-anaemic and minimally anaemic subjects. 1989 , 42, 56-8	12
2053	Chromosome 7 long arm deletion breakpoints in preleukemia: mapping by pulsed field gel electrophoresis. 1989 , 17, 1511-20	22

2052	Bone marrow biopsy and evaluation. 1989 , 19, 669-96		19
2051	DNA index and karyotype analysis in myelodysplasia. 1989 , 42, 498-501		9
2050	Bone marrow analysis of the myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia. 1989 , 57, 47-53		32
2049	Alpha-smooth muscle actin is expressed in a subset of bone marrow stromal cells in normal and pathological conditions. 1989 , 57, 291-302		53
2048	Ras genes and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1989 , 71, 1-6	4-5	28
2047	Characterization of deletions of chromosome 7 short arm occurring as primary karyotypic anomaly in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1989 , 71, 13-7	4-5	17
2046	Bone marrow histopathology of patients with severe aplastic anaemia before treatment and at follow-up. <i>British Journal of Haematology</i> , 1989 , 72, 439-44	4-5	19
2045	Prognostic significance of Auer rods in childhood acute myelogenous leukemia: results of the studies AML-BFM-78 and -83. 1989 , 17, 202-9		12
2044	Oncogenes in the myelodysplastic syndrome. 1989 , 3, 105-9		10
2043	Acute myelogenous leukaemia in children. 1989 , 148, 382-8		14
2042	Progress in the therapy of myelodysplastic syndromes. 1989 , 58, 265-70		10
2041	Cooperative effects of gamma-interferon and 1 alpha, 25-dihydroxyvitamin D3 on in vitro differentiation of the blast cells of RAEB and RAEB-T. 1989 , 58, 181-6		7
2040	Analysis of human dysplastic haematopoiesis in long-term bone marrow culture. 1989 , 59, 442-8		10
2039	Chronic myelomonocytic leukemia: natural history and prognostic determinants. 1989 , 64, 1246-54		56
2038	Prognostic significance of single chromosome abnormalities in preleukemic states. 1989 , 42, 1-7		37
2037	Refractory anemia with excess of blasts in transformation. Clinical, hematologic, and cytogenetic findings in nine patients. 1989 , 42, 55-65		7
2036	Clinical-cytogenetic correlations in myelodysplasia (preleukemia). 1989 , 40, 149-61		97
2035	Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts. 1989 , 42, 173-85		47

2034	Translocation t(6;9) occurring in acute myelofibrosis, myelodysplastic syndrome, and acute nonlymphocytic leukemia suggests multipotent stem cell involvement. 1989 , 42, 209-19		36
2033	Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. 1989 , 39, 167-79		56
2032	Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. 1989 , 86, 178-82		92
2031	[Acquired idiopathic sideroblastic anemia. Apropos of 39 cases]. 1989 , 10, 323-9		
2030	Peripheral blood morphologic changes after high-dose antineoplastic chemotherapy and recombinant human granulocyte colony-stimulating factor administration. 1989 , 92, 280-5		42
2029	8;21 translocation in acute nonlymphocytic leukemia. Occurrence in M1 and M2 FAB subtypes. 1989 , 92, 172-6		20
2028	[Incidence and prognostic significance of Auer rods in children with acute myeloid leukemia in the studies AML-BFM-78 and -83]. 1989 , 201, 227-32		1
2027	Oncogene involvement in myelodysplasia and acute myeloid leukemia. 1990 , 11 Suppl 1, 44-58		5
2026	Myelodysplastic syndrome presenting with generalized cutaneous granulocytic sarcomas. 1990 , 83, 89-93		15
2025	Chromosome Abnormalities in Chronic Myeloid Leukaemia. 1990 , 11, 3-24		7
2024	Sweet's syndrome associated with sideroblastic anaemia. 1990 , 20, 179-81		2
2023	Excessive Zinc Ingestion. 1990 , 264, 1441		63
2022	Myelodysplastic syndrome (MDS)-associated inhibitory activity on haemopoietic progenitor cells. <i>British Journal of Haematology</i> , 1990 , 74, 179-84	4.5	15
2021	Development of acute myelocytic leukemia in patients with Crohn's disease. 1990 , 35, 1553-6		18
2020	Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. 1990 , 8, 445-58		77
2019	The myelodysplastic syndromes. Case report and review. 1990 , 70, 579-83		10
2018	Successful treatment for perinephric abscess with recombinant human granulocyte colony-stimulating factor following nephrectomy in a patient of myelodysplastic syndrome: a case report. 1990 , 2, 223-6		2
2017	Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association. 1990 , 31, 250-4		13

2016	Plasma cyclic nucleotide levels in patients with refractory anaemia with excess of blasts. 1990 , 60, 177-80		1
2015	Correlations between cytogenetics and morphology in myelodysplastic syndromes. 1990 , 60, 223-7		17
2014	Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulating factor therapy for myelodysplastic syndrome. <i>American Journal of Hematology</i> , 1990 , 34, 73-4	7.1	16
2013	Chronic myelomonocytic leukemia: a test of a proposed staging system. <i>American Journal of Hematology</i> , 1990 , 35, 129-30	7.1	4
2012	Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. 1990 , 8, 1707-14		79
2011	The myelodysplastic syndromes: biology and implications for management. 1990 , 8, 1424-41		65
2010	Granulocyte maturation and the chromosome deletion 17p- in primary myelodysplastic syndrome. 1990 , 84, 77-81		5
2009	The myelodysplastic syndromes: current approaches to therapy. 1990 , 112, 932-41		73
2008	Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabioside in the treatment of patients with myelodysplastic syndromes. A phase II study. 1990 , 13, 33-7		8
2007	Apoptosis is a Common Histopathological Finding in Myelodysplasia: the Correlate of Ineffective Haematopoiesis. 1990 , 2, 415-8		81
2006	FMS mutations in myelodysplastic, leukemic, and normal subjects. 1990 , 87, 1377-80		186
2005	Molecular cloning and characterization of a defective recombinant feline leukaemia virus associated with myeloid leukaemia. 1990 , 71 (Pt 2), 343-54		36
2004	Anémie r' fractaire et connectivite, [propos d'une cas. 1990 , 11, 403-404		
2003	Prevention of diabetes mellitus in BB rats by neonatal stimulation of beta cells. 1990 , 335, 134-5		39
2002	Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. 1990 , 335, 131-4		92
2001	Flow cytometric analysis of acute leukemias. 1990 , 10, 43-50		5
2000	In vitro cytogenetic effects of recombinant human hematopoietic growth factors on cells derived from myelodysplastic syndromes. 1990 , 48, 169-78		4
1999	Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. 1990 , 44, 15-26		105

1998	Cytogenetic abnormalities in acute leukemia complicating melphalan-treated multiple myeloma. 1990 , 48, 67-73		15
1997	Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1990 , 74, 270-6	4-5	30
1996	Chromosome studies in 104 patients with polycythemia vera. 1991 , 66, 287-99		120
1995	Urticaria pigmentosa and preleukemia: evidence for reactive mast cell proliferation. 1991 , 24, 893-7		3
1994	Management of patients with myelodysplastic syndromes. 1991 , 66, 485-97		12
1993	Dysmegakaryopoiesis predicting response to therapy in acute myeloid leukaemia. A histologic and clinical study. 1991 , 187, 290-5		1
1992	Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. 1991 , 5, 117-25		18
1991	Infection in the myelodysplastic syndromes. 1991 , 90, 338-344		37
1990	Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. 1991 , 91, 612-24		142
1989	Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. 1991 , 90, 274-6		27
1988	Infection in the myelodysplastic syndromes. 1991 , 90, 338-344		74
1987	Reciprocal translocation involving 3q21 in an unusual myeloproliferative disorder with myelodysplastic features and prominent dysmegakaryopoiesis. 1991 , 51, 73-8		3
1986	8;21 translocation with duplication of the der(21) in a patient with myelomonocytic leukemia. 1991 , 51, 139-41		8
1985	Partial trisomy 1q. A nonrandom primary chromosomal abnormality in myelodysplastic syndromes?. 1991 , 56, 243-53		49
1984	Genetic abnormalities in myelodysplastic syndrome. 1991 , 56, 1-6		12
1983	Role of interleukin-4 in the negative regulation of proliferation of chronic myelomonocytic leukemia cells. 1991 , 628, 156-64		4
1982	Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate. 1991 , 48, 451-5		16
1981	Detection of trisomy 8 in hematological disorders by in situ hybridization. 1991 , 56, 132-6		49

1980	Myelodysplastic syndrome and acquired factor VIII inhibitor with severe subcutaneous haemorrhage. 1991 , 85, 206-8		14
1979	The bone marrow in human immunodeficiency virus (HIV)-related disease. Morphology and clinical correlation. 1991 , 95, 63-71		128
1978	Evolution of the French-American-British (FAB) proposals. Is there a place for acute basophilic leukemia?. 1991 , 96, 153-5		11
1977	Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia. 1991 , 95, 556-60		4
1976	Leukemia and lymphoma immunophenotyping in cell smears with immunogold-silver staining. 1991 , 96, 351-9		5
1975	Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion. 1991 , 88, 6176-80		44
1974	Granulocyte-monocyte and Granulocyte-Colony Stimulating Factors in Myelodysplastic Syndromes. 1991 , 5, 219-30		2
1973	Treatment of Myelodysplastic Syndromes with Orally Administered N-(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine (Ubenimex)*. 1991 ,		
1972	Treatment of myelodysplastic syndromes. 1991 , 5, 42-50		12
1971	Proposed criteria for classification of acute myeloid leukemia in dogs and cats. 1991 , 20, 63-82		93
1970	Chromosome 16 abnormalities associated with myeloid malignancies. 1991 , 3, 55-61		44
1969	The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 1991 , 38, 67-8	7.1	45
1968	Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome. 1991 , 63, 270-5		15
1967	Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. 1991 , 63, 297-301		9
1966	The effect of recombinant alpha-interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome. 1991 , 62, 225-9		3
1965	Early Pre-B Lymphoblastic Transformation in A Patient with Refractory Anemia. 1991 , 3, 301-3		
1964	Comparative ferrokinetic study with initial and extended iron clearance models. 1991 , 44, 395-9		4
1963	Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens. 1991 , 44, 300-5		24

1962	Globin chain synthesis in myelodysplastic syndromes. 1991 , 44, 134-8	5
1961	Two Cases of Translocation t(3;6)(p14;p22): A Non Random Chromosomal Abnormality?. 1991 , 5, 423-9	
1960	Dysmyelopoietic Features and Bone Marrow Histology in 30 Cases of Primary Myelodysplastic Syndromes. 1991 , 3, 419-22	2
1959	Basic blue 75: a new stain for erythroblasts. 1991 , 66, 259-65	
1958	FABHELP: A Rule-Based Consultation Program for FAB Classification of Acute Myeloid Leukemia and Myelodysplastic Syndromes. 1991 , 22, 639-643	3
1957	[Myelodysplastic diseases in childhood]. 1992 , 204, 190-7	5
1956	Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. 1992 , 7, 343-50	27
1955	Myelodysplastic Syndrome. 1992 , 267, 2077	
1954	Further evidence for differential regulation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH): increased FSH and decreased LH levels in a patient with familial pure gonadal dysgenesis. 1992 , 68, 925-7	1
1953	Myelodysplastic syndromes. 1992 , 67, 962-6	17
1952	Oncogene expression in primary myelodysplasia: correlation with haematological, karyotypic, and clinical progression. 1992 , 45, 339-43	7
1951	Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia. 1992 , 45, 855-9	16
1950	Cytogenetic evidence for extramedullary blast crisis with t(8;13)(q11;p11) in chronic myelomonocytic leukemia. 1992 , 88, 201-3	16
1949	Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. 1992 , 98, 502-10	43
1948	Dysplastic megakaryopoiesis with thrombocytopenia and chromosomal aberration. 1992 , 98, 227-30	3
1947	Bone marrow dysplasia. A continuing diagnostic challenge. 1992 , 98, 473-5	7
1946	Ph-Negative Chronic Myeloid Leukemia: The Nature of the Breakpoint Junctions and Mechanism of ABL Transposition. 1992 , 6, 277-287	3
1945	A two step stain for normal and leukemic monocytes using two different dyes applied in sequence. 1992 , 67, 68-72	2

1944	Macrophages (phagocytic-histiocytic reticular cells) in reactive-inflammatory lesions of the bone marrow and in myelodysplastic syndromes (MDS). An immunohistochemical and morphometric study by use of a new monoclonal antibody (PG-M1). 1992 , 188, 995-1001	9
1943	Cell-cycle progression rates and sister chromatid exchange frequencies in the bone marrow of patients with myelodysplastic syndrome and acute myeloid leukemia. 1992 , 62, 66-9	8
1942	Trisomy of chromosome 8 in myelodysplastic syndrome. Significance of the fluctuating trisomy 8 population. 1992 , 62, 70-4	30
1941	Trisomy 8 and 11 in refractory anemia with excess blasts in transformation (RAEB-T). 1992 , 62, 98-9	1
1940	Cytohematologic and cytogenetic prognostic factors at diagnosis and in the evolution in 46 primary myelodysplastic syndromes. 1992 , 61, 174-82	16
1939	Predominance of chromosome 5 deletions in myeloid neoplasia associated with solid tumors managed by surgical excision. 1992 , 58, 125-9	
1938	Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. 1992 , 59, 138-60	92
1937	Cytogenetic and molecular studies of the Philadelphia translocation in myelodysplastic syndromes. Report of two cases and review of the literature. 1992 , 59, 161-6	28
1936	Deletion of the long arm of chromosome 5 in essential thrombocythemia. 1992 , 61, 93-5	9
1935	Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression. 1992 , 43, 516-60	47
1934	The association between the myelodysplastic syndromes and Crohn disease. 1992 , 117, 661-2	35
1933	Deformability of the erythrocyte membrane in patients with myelodysplastic syndromes. 1992 , 87, 169-72	6
1932	Acute Myelocytic Leukemia and Chronic Myelomonocytic Leukemia Simultaneously with Resectable Breast Cancer: A Report of two Cases. 1992 , 78, 356-358	2
1931	Biologic Relevance of Elevated Red Cell Adenosine Deaminase Activity in Myelodysplastic Syndromes and Paroxysmal Nocturnal Hemoglobinuria. 1992 , 78, 370-373	1
1930	Cardiac Tamponade in Chronic Myelomonocytic Leukemia: A Case Report. 1992 ,	
1929	A Guide to Risk Assessment in the Primary Myelodysplastic Syndrome. 1992 , 6, 587-606	41
1928	Molecular Genetic Aspects of Myelodysplastic Syndromes. 1992 , 6, 557-570	35
1927	Issues in the Pathology of the Myelodysplastic Syndromes. 1992 , 6, 501-522	17

1926	Coincidence of primary myelodysplastic syndrome and non-Hodgkin lymphoma. 1992 , 70, 1082-4		4
1925	Unusual cutaneous lesions associated with chronic myelomonocytic leukaemia. 1992 , 17, 121-4		17
1924	Clinical trials of bestatin for leukemia and solid tumors. 1992 , 4, 205-14		30
1923	Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts: a critical evaluation by immunohistochemistry, cytochemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes. 1992 , 62, 275-82		16
1922	Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. 1992 , 64, 16-21		44
1921	Hypoplastic acute leukemia: description of eight cases and search for hematopoietic inhibiting activity. 1992 , 65, 247-52		5
1920	Expression of the Tn antigen on erythroid cells from a patient with Tn syndrome. 1992 , 37, 271-83		1
1919	The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. 1992 , 65, 162-8		114
1918	Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. 1992 , 65, 17-21		18
1917	Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1992 , 80, 121-4	4.5	39
1916	Myelodysplastic syndrome (MDS)-associated inhibitory activity on haematopoietic progenitor cells: contribution of monocyte-derived lipid containing macrophages (MDLM). <i>British Journal of Haematology</i> , 1992 , 81, 67-72	4.5	6
1915	The cytogenetics of haematological malignancies. 1992 , 5, 791-814		5
1914	Myeloid malignancies and chromosome 5 deletions. 1992 , 5, 931-42		12
1913	The management of acute myelogenous leukemia in the elderly: ten-year experience in 118 patients. <i>Hematological Oncology</i> , 1992 , 10, 251-60	1.3	15
1912	Successful treatment with vincristine by slow infusion in a patient with refractory anemia and excess of blasts. <i>American Journal of Hematology</i> , 1992 , 39, 73-4	7.1	1
1911	Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents. 1992 , 70, 77-85		40
1910	8;21 translocation and multilineage involvement. <i>American Journal of Hematology</i> , 1993 , 43, 211-215	7.1	
1909	Karyotypic analysis in primary myelodysplastic syndromes. 1993 , 7, 10-8		19

1908	High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1993 , 84, 232-7	4.5	39
1907	Myelodysplastic syndrome with eosinophilia in bone marrow. Gunma Haematology Study Group. <i>British Journal of Haematology</i> , 1993 , 84, 636-8	4.5	17
1906	Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. <i>British Journal of Haematology</i> , 1993 , 83, 158-65	4.5	61
1905	Proliferation and differentiation of myelodysplastic CD34+ cells in serum-free medium: response to individual colony-stimulating factors. <i>British Journal of Haematology</i> , 1993 , 83, 349-58	4.5	20
1904	The CD11/CD18 granulocyte adhesion molecules in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1993 , 83, 245-52	4.5	10
1903	Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. 1993 , 11, 49-55		23
1902	Classification of myeloproliferative disorders in cats using criteria proposed by the animal leukaemia study group: A retrospective study of 181 cases (1969-1992). 1993 , 3, 125-134		28
1901	Clinico-hematological profile and natural history of childhood myelodysplastic syndromes. 1993 , 60, 573-81		8
1900	Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. 1993 , 66, 85-91		30
1899	Biology and treatment of myelodysplastic syndromes--developments in the past decade. 1993 , 66, 107-15		21
1898	Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. 1993 , 66, 117-22		75
1897	Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. 1993 , 66, 175-80		21
1896	Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes. 1993 , 423, 33-8		8
1895	Myelodysplastic syndrome: diagnostic implications of cytochemical and immunocytochemical studies. 1993 , 68, 47-53		14
1894	Clinical and cytogenetic significance of myelodysplastic syndromes with disease evolution. 1993 , 67, 71-8		9
1893	Consistent interstitial chromosomal deletions in myeloid malignancies and their correlation with fragile sites. 1993 , 65, 51-7		11
1892	Translocation (12;14)(q13;q32) in myelodysplastic syndrome. 1993 , 65, 76-8		3
1891	Childhood myelodysplastic syndrome with clonal evolution progressing to acute megakaryoblastic leukemia (ANLL-M7). 1993 , 70, 17-20		4

1890	Cell lineage involvement in four patients with myelodysplastic syndrome and t(1;7) or trisomy 8 studied by simultaneous immunophenotyping and fluorescence in situ hybridization. 1993 , 70, 120-4	31
1889	Expression of the proliferating cell nuclear antigen in bone marrow cells from patients with myelodysplastic syndromes and aplastic anemia. 1993 , 24, 359-63	27
1888	Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias. 1993 , 11, 509-16	6
1887	Myelodysplastic Syndromes. 1993 , 24, 712-716	4
1886	The role of interleukin-4 in the negative regulation of leukemia cell growth. 1993 , 9, 205-9	17
1885	Common haematological problems in the elderly. 1993 , 3, 335-346	
1884	Lymph node disease with lymphocytic abnormal chromatin clumping in a myelodysplastic/myeloproliferative syndrome. 1993 , 46, 177-9	1
1883	Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. 1993 , 90, 65-70	19
1882	Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia. 1993 , 89, 189-94	13
1881	Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. 1993 , 90, 5484-8	197
1880	Leukemia cutis. Analysis of 50 biopsy-proven cases with an emphasis on occurrence in myelodysplastic syndromes. 1993 , 100, 276-84	121
1879	Rapid detection of plasma glycofibrin by a latex agglutination test. A useful adjunct in the differential diagnosis of thrombocytopenia. 1993 , 100, 579-84	11
1878	Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. 1993 , 99, 513-25	56
1877	New uses for old vitamins. The treatment of myelodysplastic disorders. 1993 , 77, 919-29	2
1876	Quantitative and qualitative characteristics of colony-forming unit-erythroid colonies in myelodysplastic syndrome patients. 1993 , 90, 1-4	3
1875	Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy. 1993 , 89, 141-3	8
1874	Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. 1993 , 90, 58-64	22
1873	Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. 1993 , 11, 1448-57	123

1872	Interleukin-4 in chronic myelomonocytic leukemia. Growth suppression of hematopoietic precursors in the chronic phase and stimulation in the acute phase. 1994 , 92, 104-8		1
1871	The Use of Hemopoietic Growth Factors in the Treatment of Myelodysplastic Syndromes. 1994 , 204-219		
1870	Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. 1994 , 12, 671-8		262
1869	Low-dose ara-C in myelodysplastic syndromes (MDS) and acute leukemia following MDS: proposal for a predictive model. 1994 , 12, 343-51		8
1868	Reticulocyte maturity as an indicator for estimating qualitative abnormality of erythropoiesis. 1994 , 47, 736-9		27
1867	Myelodysplastic syndromes in childhood--classification, epidemiology, and treatment. 1994 , 13, 11-26		78
1866	Expression and genomic configuration of GM-CSF, IL-3, M-CSF receptor (C-FMS), early growth response gene-1 (EGR-1) and M-CSF genes in primary myelodysplastic syndromes. 1994 , 15, 135-41		4
1865	Immunological findings in patients with myelodysplastic syndrome. 1994 , 15, 201-8		9
1864	Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis. 1994 , 14, 111-20		13
1863	Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. 1994 , 68, 167-70		4
1862	Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: evidence for a shortening of the granulocyte release time. 1994 , 68, 175-81		2
1861	CD 34 immunotyping of blasts in myelodysplasia. 1994 , 68, 77-80		13
1860	Myelodysplastic syndromes in childhood: description of seven cases. 1994 , 68, 241-5		2
1859	Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. <i>British Journal of Haematology</i> , 1994 , 87, 171-84	4.5	72
1858	Dysplastic haemopoiesis following orthotopic liver transplantation: comparison with similar changes in HIV infection and primary myelodysplasia. <i>British Journal of Haematology</i> , 1994 , 88, 685-92	4.5	17
1857	Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies. <i>British Journal of Haematology</i> , 1994 , 88, 778-83	4.5	18
1856	Establishing the incidence of myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1994 , 87, 743-5	4.5	121
1855	The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. <i>British Journal of Haematology</i> , 1994 , 87, 746-54	4.5	369

1854	The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry. <i>British Journal of Haematology</i> , 1994 , 87, 477-82	4-5	14
1853	Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan. 1994 , 74, 40-9		41
1852	Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. 1994 , 74, 62-5		21
1851	Involvement of erythrocytic and granulomonocytic lineages by trisomy 11 in two cases of acute myelomonocytic leukemia with trilineage myelodysplasia. An interphase cytogenetic study. 1994 , 77, 33-8		7
1850	Myelodysplastic syndrome in a quarter horse gelding. 1994 , 26, 83-5		18
1849	Histological characteristic of bone marrow trephines in myelodysplastic syndromes. 1994 , 1, 189-193		
1848	Identification and treatment of anaemia in older patients. 1994 , 4, 113-27		18
1847	Cancer Incidence in Atomic Bomb Survivors. Part III: Leukemia, Lymphoma and Multiple Myeloma, 1950-1987. 1994 , 137, S68		514
1846	New treatment approaches for myelodysplastic syndrome and secondary leukaemias. 1994 , 5, 401-8		10
1845	The electrokinetic behavior of red blood cells from a patient with Tn syndrome by Doppler electrophoretic light scattering analysis. 1994 , 174, 369-77		6
1844	Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. 1994 , 70, 969-72		223
1843	Hair dye use and other risk factors for leukemia and pre-leukemia: a case-control study. Italian Leukemia Study Group. 1994 , 139, 609-19		74
1842	Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious diseases. 1994 , 101, 123-9		45
1841	Myelodysplastic Syndrome Associated with Immunoblastic Lymphadenopathy-like T-Cell Lymphoma: Simultaneous Clinical Improvement with Chemotherapy. 1994 ,		
1840	Myelodysplasia with myelofibrosis--a distinct subgroup within the myelodysplastic syndromes. 1994 , 26, 69-71		5
1839	Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. 1995 , 92, 10560-4		741
1838	p53 mutation in the myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1995 , 89, 61-6	4-5	25
1837	Hyperthyroidism. 1995 , 122, 393		1

1836	Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1995 , 90, 15-21	4.5	22
1835	Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. <i>British Journal of Haematology</i> , 1995 , 91, 403-8	4.5	203
1834	The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. <i>British Journal of Haematology</i> , 1995 , 90, 602-6	4.5	34
1833	Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. <i>British Journal of Haematology</i> , 1995 , 89, 188-90	4.5	50
1832	Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide. 1995 , 103, 29-36		9
1831	Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der(1q;7p) chromosomal abnormality. <i>American Journal of Hematology</i> , 1995 , 50, 110-5	7.1	29
1830	Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems. <i>Hematological Oncology</i> , 1995 , 13, 139-52	1.3	7
1829	FAB classification of myelodysplastic syndromes: merits and controversies. 1995 , 71, 3-11		32
1828	Comparison of scoring systems in primary myelodysplastic syndromes. 1995 , 70, 301-8		6
1827	Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome. 1995 , 71, 293-9		7
1826	Heterogeneity of lineage involvement by trisomy 8 in myelodysplastic syndrome. A multiparameter analysis combining conventional cytogenetics, DNA in situ hybridization, and bone marrow culture studies. 1995 , 82, 116-22		21
1825	Chronic myelomonocytic leukemia with a novel t(5;18) translocation. 1995 , 85, 89		3
1824	An unusual cytogenetic abnormality involving chromosomes 1 and 7 in a case of chronic myelomonocytic leukemia. 1995 , 85, 75-7		3
1823	The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes. 1995 , 121, 338-42		4
1822	Granulocyte colony-stimulating factor in acute myeloid leukemia. 1995 , 13, 647-54		9
1821	Hyperthyroidism. 1995 , 122, 393-4		
1820	Anaphylactoid reactions to ciprofloxacin. 1995 , 122, 396-7		15
1819	Nonsteroidal Anti-inflammatory Drugs and High Blood Pressure. 1995 , 122, 397		

1818	Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. 1995 , 13, 2973-9	53
1817	Helicobacter pylori and peptic ulcer. 1995 , 122, 394-5	
1816	Transient ischemic attack after air contrast echocardiography in patients with septal aneurysm. 1995 , 122, 396	5
1815	Castleman disease and renal amyloidosis. 1995 , 122, 395-6	14
1814	Pharmacoepidemiology of Niacin. 1995 , 122, 392	
1813	Presidential address. May 22, 1995 Thirty-First Annual Meeting of the American Society of Clinical Oncology. 1995 , 13, 2980-9	2
1812	QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens. 1995 , 48, 291-4	22
1811	Expression of cd34 and p-glycoprotein - prognostic-significance in primary myelodysplastic syndromes. 1995 , 7, 901-5	
1810	Chromosomal deletions in myelodysplasia. 1995 , 17, 71-8	32
1809	Hereditary thrombocytopenias in childhood. 1995 , 21, 294-304	14
1808	Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. 1995 , 18, 457-63	20
1807	Myelodysplasia and deficiency of uridine diphosphate-galactose 4-epimerase. 1995 , 127, 605-8	9
1806	Myelodysplastic (preleukemia) syndromes: the bone marrow factory failure problem. 1995 , 70, 673-6; quiz 677	7
1805	Clinical Features of Hematopoietic Malignancies and Related Disorders among Benzene-Exposed Workers in China. 1996 , 104, 1353	25
1804	Bone remodeling alterations in myelodysplastic syndrome. 1996 , 19, 401-5	24
1803	The process of leukemogenesis. 1996 , 104 Suppl 6, 1239-46	34
1802	Acute myelomonocytic leukaemia with 11q23 abnormality during multiple myeloma: is this related to anthracycline?. 1996 , 95, 144-7	2
1801	Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. 1996 , 14, 1320-6	137

1800	Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. 1996 , 14, 2486-94		43
1799	Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 1996 , 14, 220-6		97
1798	Clinical features of hematopoietic malignancies and related disorders among benzene-exposed workers in China. Benzene Study Group. 1996 , 104 Suppl 6, 1353-64		27
1797	CD117/CD34 expression in leukemic blasts. 1996 , 106, 192-5		53
1796	Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. 1996 , 106, 676-9		34
1795	Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. 1996 , 106, 680-8		76
1794	Effects of myeloid cell growth factors on alkaline phosphatase, myeloperoxidase, defensin and granulocyte colony-stimulating factor receptor mRNA expression in haemopoietic cells of normal individuals and myeloid disorders. <i>British Journal of Haematology</i> , 1996 , 92, 9-22	4.5	11
1793	Dicentric (1;15) in myeloid disorders. 1996 , 88, 86-9		13
1792	The relationship between age and karyotypic abnormalities in myelodysplastic syndromes. 1996 , 88, 80-2		2
1791	Myelodysplastic syndromes in the elderly: the role of growth factors in management. 1996 , 20, 203-19		30
1790	Successful coronary artery bypass grafting for a patient with myelodysplastic syndrome: report of a case. 1996 , 26, 740-3		6
1789	Immunotyping of blasts in human bone marrow. 1996 , 72, 125-9		13
1788	Detection of partial cDNA sequences differentially expressed in patients with myelodysplasia. 1996 , 72, 231-6		3
1787	Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukemia: a case report and cell lineage study. 1996 , 73, 35-8		31
1786	Stromal abnormalities in neoplastic bone marrow diseases. 1996 , 73, 53-70		86
1785	Cytogenetic analysis in patients with primary myelodysplastic syndromes in leukaemic transformation. A report on 94 cases. Groupe Français de Cytog ⁿ n ^t ique H ^é matologique (GFCH). 1996 , 38, 177-81		25
1784	Myelodysplasia in childhood may be a polyclonal disease. 1996 , 38, 325-30		3
1783	Myelodysplastic syndromes. 1996 , 38, 363-80		33

1782	Simultaneous development of Crohn's disease and myelodysplastic syndrome progressing to acute myelocytic leukemia in a patient with a normal karyotype. 1996 , 31, 599-602		14
1781	Rheumatic manifestations of the myelodysplastic syndromes: a comparative study. 1996 , 26, 683-8		16
1780	Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: study of nine cases. 1996 , 92, 31-6		27
1779	Special cytological subtypes of acute myeloid leukaemias and myelodysplastic syndromes. 1996 , 9, 19-33		6
1778	Treatment and prognostic factors in myelodysplastic syndromes. 1996 , 9, 161-83		19
1777	Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study. French Society of Paediatric Haematology and Immunology. <i>British Journal of Haematology</i> , 1996 , 92, 344-50	4.5	74
1776	Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: an example of the 8p11 myeloproliferative disorder?. <i>British Journal of Haematology</i> , 1996 , 92, 692-5	4.5	29
1775	Response of myelodysplastic syndrome marrow progenitor cells to stimulation with cytokine combinations in a stroma-free long-term culture system. <i>British Journal of Haematology</i> , 1996 , 92, 548-54	4.5	15
1774	Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1996 , 92, 351-9	4.5	48
1773	Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1996 , 92, 360-4	4.5	34
1772	Deletions of the long arm of chromosome 7 in myeloid disorders: loss of band 7q32 implies worst prognosis. <i>British Journal of Haematology</i> , 1996 , 92, 574-81	4.5	46
1771	Granulocytic sarcoma of the uterus complicating myelodysplastic syndrome. <i>American Journal of Hematology</i> , 1996 , 51, 244-5	7.1	2
1770	Chronic consumption coagulopathy and popliteal aneurysm. <i>American Journal of Hematology</i> , 1996 , 51, 245-6	7.1	3
1769	Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome. <i>American Journal of Hematology</i> , 1996 , 53, 143-4	7.1	4
1768	Parathyroid hormone-related protein-associated hypercalcemia in probable intravascular lymphoma of B-cell type. <i>American Journal of Hematology</i> , 1996 , 53, 144-5	7.1	8
1767	Cytog ⁿ n ^t ique des syndromes my ⁿ lodysplasiques. 1996 , 1996, 26-32		
1766	Apport des cultures de moelle dans les syndromes my ⁿ lodysplasiques. 1996 , 1996, 39-44		
1765	Traitement des syndromes my ⁿ lodysplasiques. 1996 , 1996, 93-96		

1764	Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. <i>British Journal of Haematology</i> , 1996 , 93, 45-52	4.5	10
1763	Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1996 , 93, 59-67	4.5	100
1762	Molecular characterization of the 7q deletion in myeloid disorders. <i>British Journal of Haematology</i> , 1996 , 93, 75-80	4.5	43
1761	Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. <i>British Journal of Haematology</i> , 1996 , 94, 112-5	4.5	30
1760	Myelodysplastic syndrome with karyotype abnormality is associated with elevated F-cell production. <i>British Journal of Haematology</i> , 1996 , 93, 601-5	4.5	15
1759	Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1996 , 93, 594-600	4.5	24
1758	Myelodysplastic syndromes in children. <i>British Journal of Haematology</i> , 1996 , 93, 977-8	4.5	1
1757	Pregnancy in women with essential thrombocythaemia. <i>British Journal of Haematology</i> , 1996 , 93, 977	4.5	2
1756	Haematological abnormalities in Shwachman-Diamond syndrome. <i>British Journal of Haematology</i> , 1996 , 94, 279-84	4.5	151
1755	The behaviour of red cells in narrow tubes in vitro as a model of the microcirculation. <i>British Journal of Haematology</i> , 1996 , 94, 266-72	4.5	22
1754	The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. <i>British Journal of Haematology</i> , 1996 , 94, 288-99	4.5	152
1753	Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. <i>British Journal of Haematology</i> , 1996 , 95, 349-53	4.5	130
1752	Is apoptosis a massive process in myelodysplastic syndromes?. <i>British Journal of Haematology</i> , 1996 , 95, 368-71	4.5	72
1751	Serum thrombopoietin level in various hematological diseases. 1996 , 14, 558-65		48
1750	Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. 1996 , 74, 288-90		55
1749	Prognostic implications in myelodysplastic syndromes: A review of 62 cases. 1996 , 21, 479-84		1
1748	Determination of interferon-alpha-producing capacity in whole blood cultures from patients with various diseases and from healthy persons. 1996 , 16, 911-8		23
1747	Analytical and clinical implications of soluble transferrin receptors in serum. 1996 , 34, 645-9		4

1746	Unexplained macrocytosis in elderly patients. 1996 , 25, 310-2	31
1745	Classical morphology, esterase cytochemistry, and interphase cytogenetics of peripheral blood and bone marrow smears. 1996 , 44, 1303-9	15
1744	Proliferation and differentiation of myelodysplastic CD34+ cells. 1996 , 22, 43-51	9
1743	Clonality switch in acute myeloid leukemia. 1996 , 22, 125-30	2
1742	Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. 1997 , 25, 225-32	25
1741	Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. 1997 , 89, 1065-71	262
1740	Autoimmune phenomena in patients with myelodysplastic syndromes. 1997 , 24, 483-9	85
1739	Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. 1997 , 107, 653-60	34
1738	Indications and timing of allogeneic bone marrow transplantation in myelodysplastic syndromes. 1997 , 27, 475-85	3
1737	Chromosome 7 and Haematological Malignancies. 1997 , 2, 359-72	
1736	Anaesthetic management of caesarean section in a parturient with acute myelodysplastic syndrome. 1997 , 6, 270-3	2
1735	Myelodysplasia and the leukemias. 1997 , 43, 505-97	4
1734	Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. 1997 , 15, 466-75	187
1733	Combined method for simultaneous morphology, immunophenotype and karyotype (MAC) in leukemias. 1997 , 115, 1336-42	2
1732	Myelodysplastic syndromes (MDS): prognostic factors and scoring systems. 1997 , 115, 1537-41	
1731	The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. 1997 , 94, 3899-902	45
1730	The expression of transferrin receptors on erythroblasts in anaemia of chronic disease, myelodysplastic syndromes and iron deficiency. 1997 , 97, 127-31	34
1729	Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de R ^e flexion en H ^e matologie. 1997 , 11, 16-21	32

1728	Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. 1997 , 11, 674-9	43
1727	Forty-four cases of childhood myelodysplasia with cytogenetics, documented by the Groupe Français de Cytog ⁿ tique H ⁿ matologique. 1997 , 11, 1478-85	29
1726	Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. 1997 , 11, 2188-91	29
1725	Evidence for two molecular steps in the pathogenesis of myeloid disorders associated with deletion of chromosome 7 long arm. 1997 , 11, 2097-104	17
1724	Pericentric inversion of chromosome 16 and eosinophilia in chronic myelomonocytic leukemia. 1997 , 94, 99-102	4
1723	A novel chromosomal abnormality involving chromosomes 2 and 18 in a patient with myelodysplastic syndrome. 1997 , 96, 7-12	1
1722	[Liver involvement in hematologic diseases]. 1997 , 38, 977-83	
1721	Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value. 1997 , 74, 11-4	20
1720	S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. 1997 , 74, 205-8	16
1719	A 75-year-old woman with fatigue, monocytosis, and hypothyroidism. 1997 , 75, 173-7	1
1718	Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. 1997 , 39, 277-94	12
1717	Neurogenic potential of Ewing's sarcoma cells. 1997 , 430, 41-6	21
1716	La pathologie maligne du monocyte A. Aspects cliniques et morphologiques. 1997 , 1997, 26-32	
1715	Trisomy 14 is a non-random karyotypic abnormality associated with myeloid malignancies. <i>British Journal of Haematology</i> , 1997 , 98, 177-85	4.5 13
1714	Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1997 , 98, 108-13	4.5 29
1713	Cancer in relatives of children with myelodysplastic syndrome, acute and chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1997 , 97, 127-31	4.5 21
1712	Alterations of p53 and Rb genes in a novel human GM-CSF-dependent myeloid cell line (OHN-GM) established from therapy-related leukaemia. <i>British Journal of Haematology</i> , 1997 , 98, 392-8	4.5 18
1711	Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. <i>British Journal of Haematology</i> , 1997 , 98, 983-91	4.5 61

1710	Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. <i>British Journal of Haematology</i> , 1997 , 99, 625-31	4.5	104
1709	Antithymocyte globulin for patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1997 , 99, 699-705	4.5	239
1708	Genetic analysis of 8;21 chromosomal translocation without AML1 gene involvement in MDS-AML. <i>British Journal of Haematology</i> , 1997 , 99, 632-40	4.5	5
1707	Amount of mpl on bone marrow haemopoietic precursor cells from healthy volunteers and patients with refractory anaemia. <i>British Journal of Haematology</i> , 1997 , 99, 746-55	4.5	13
1706	Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. <i>British Journal of Haematology</i> , 1997 , 96, 749-56	4.5	69
1705	Incidence of apoptosis in HIV-myelopathy, myelodysplastic syndromes and non-specific inflammatory lesions of the bone marrow. 1997 , 30, 307-11		11
1704	Pyridoxin-responsive anaemia in a patient with a history of polycythaemia vera. 1997 , 242, 79-81		1
1703	Myelodysplastic syndrome with vasculitic manifestations. 1997 , 242, 425-31		14
1702	Systemic vasculitis and myelodysplastic syndromes. A report of two cases. 1997 , 40, 179-82		21
1701	Telomere length in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 1997 , 56, 266-71	7.1	62
1700	dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. 1997 , 20, 282-91		51
1699	Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. 1997 , 79, 1548-51		108
1698	Myelodysplastische Syndrome. 1998 , 39, 1168-1180		3
1697	Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 1998 , 21, 255-61		144
1696	DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. 1998 , 12, 242-6		2
1695	The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. 1998 , 12, 652-9		23
1694	Myelodysplastic syndromes associated with 11q23 abnormalities. European 11q23 Workshop participants. 1998 , 12, 834-9		34
1693	RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. 1998 , 12, 887-92		188

1692	Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. 1998 , 12, 1187-94		37
1691	Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. 1998 , 12, 1331-2		4
1690	Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes. 1998 , 12, 1655-6		20
1689	Translocation (1;22) in refractory anemia and the prognostic significance of karyotypic abnormalities in refractory anemia. 1998 , 106, 72-5		1
1688	Trisomy 6 is the hallmark of a dysplastic clone in bone marrow aplasia. 1998 , 105, 55-9		14
1687	A new translocation (4;12)(q21;q15) after combined immunosuppressive therapy in a case of hypoplastic myelodysplastic syndrome with translocation (12;15)(q23;q12). 1998 , 107, 82-4		1
1686	Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization. 1998 , 106, 110-5		6
1685	Childhood myeloproliferative disorders. 1998 , 11, 875-98		3
1684	Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. 1998 , 41, 1493-6		17
1683	Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content, and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells. 1998 , 32, 28-36		40
1682	Sideroblastic anemias: variations on imprecision in diagnostic criteria, proposal for an extended classification of sideroblastic anemias. <i>American Journal of Hematology</i> , 1998 , 57, 1-6	7.1	15
1681	Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes. <i>American Journal of Hematology</i> , 1998 , 57, 113-8	7.1	10
1680	Simultaneous occurrence of lupus anticoagulant and factor VIII inhibitors in hemophilia. <i>American Journal of Hematology</i> , 1998 , 58, 248	7.1	2
1679	Polycythemia vera in a patient with acquired immunodeficiency syndrome. <i>American Journal of Hematology</i> , 1998 , 58, 248-9	7.1	3
1678	Prothrombin gene 20210 G-A mutation in the Turkish population. <i>American Journal of Hematology</i> , 1998 , 58, 249	7.1	61
1677	Elevated beta 2-microglobulin in lymphorrhoea from immunoblastic lymphoma. <i>American Journal of Hematology</i> , 1998 , 58, 249-50	7.1	4
1676	Are sickle cell disease patients with stroke genetically predisposed to the event by inheriting a tendency to high tumor necrosis factor levels?. <i>American Journal of Hematology</i> , 1998 , 58, 250	7.1	4
1675	Usefulness of IPSS for the patients with refractory anemia. <i>American Journal of Hematology</i> , 1998 , 58, 250-2	7.1	10

1674	Vibrio vulnificus sepsis associated with coincidental diagnosis of acute myeloid leukemia. <i>American Journal of Hematology</i> , 1998 , 58, 252	7.1	0
1673	Infiltration of the central nervous system as a presentation form of early stage chronic lymphocyte leukemia. <i>American Journal of Hematology</i> , 1998 , 58, 339-40	7.1	9
1672	Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine. <i>American Journal of Hematology</i> , 1998 , 58, 340-1	7.1	7
1671	Congenital spherocytic hemolytic anemia in a family presenting with transient red cell aplasia from parvovirus B19 infection. <i>American Journal of Hematology</i> , 1998 , 58, 341-2	7.1	3
1670	Progression of a myelodysplastic syndrome with trisomy 8 to acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 1998 , 58, 342	7.1	5
1669	Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. 1998 , 22, 251-6		61
1668	Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases. 1998 , 23, 337-49		37
1667	Microsatellite instability is rare in the clinical course of myelodysplastic syndrome studied with DNA from fresh and paraffin-embedded tissues. 1998 , 124, 231-5		10
1666	Platelet dysfunction as the presenting feature of atypical myelodysplastic syndrome with monosomy 7, normal blood counts and no bleeding tendency. 1998 , 15, 275-8		2
1665	Hemoglobin F in myelodysplastic syndrome. 1998 , 76, 135-8		23
1664	Myelodysplasia presenting with pulmonary manifestations associated with neutrophilic dermatosis. 1998 , 77, 135-8		25
1663	Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia. 1998 , 77, 261-4		25
1662	Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. <i>British Journal of Haematology</i> , 1998 , 100, 304-9	4.5	157
1661	Vitamin D treatment in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 100, 516-20	4.5	38
1660	Association of myelodysplastic changes with purine analogues. <i>British Journal of Haematology</i> , 1998 , 100, 677-9	4.5	32
1659	Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. <i>British Journal of Haematology</i> , 1998 , 100, 784-92	4.5	48
1658	Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 101, 220-30	4.5	76
1657	Significance of trilineage myelodysplasia in de novo acute myeloid leukaemia during remission rather than at diagnosis. <i>British Journal of Haematology</i> , 1998 , 101, 743-8	4.5	7

1656	Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 102, 465-74	4.5	69
1655	Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. <i>British Journal of Haematology</i> , 1998 , 102, 486-94	4.5	35
1654	Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. <i>British Journal of Haematology</i> , 1998 , 102, 678-83	4.5	30
1653	Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. <i>British Journal of Haematology</i> , 1998 , 103, 189-97	4.5	60
1652	Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 103, 778-84	4.5	24
1651	A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 103, 1070-4	4.5	156
1650	'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. <i>British Journal of Haematology</i> , 1998 , 103, 1075-82	4.5	82
1649	Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1998 , 102, 778-784	4.5	
1648	Acute myeloid leukaemias. 1998 , 34, 862-72; discussion 871-2		14
1647	Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors. 1998 , 10, 97-109		4
1646	Bersicht. 1998 , 22, 199-206		2
1645	Pyrexia of unknown origin, the age-old dilemma. 1998 , 74, 761-3		
1644	Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. 1998 , 29, 547-51		16
1643	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1998. A 51-year-old man with myelodysplasia and a pulmonary infiltrate. 1998 , 338, 453-61		8
1642	"The slow code". 1998 , 338, 1921; author reply 1922-3		5
1641	Treatment of paraphilia with an analogue of gonadotropin-releasing hormone. 1998 , 338, 1923; author reply 1923-4		1
1640	The response of early gastric cancer to proton-pump inhibitors. 1998 , 338, 1924-5		21
1639	Clinical Problem-Solving: A Square Peg in a Round Hole. 1998 , 338, 1926-1927		

1638 Ephedrine is not phenylephrine. **1998**, 338, 1927

1637 More on varicella immunization. **1998**, 338, 1927

4

1636 Preemptive liver transplantation from a living related donor for primary hyperoxaluria type I. **1998**, 338, 1924

36

1635 Case 5-1998: bone marrow blasts in chronic myelomonocytic leukemia. **1998**, 338, 1925-6

1634 Elevated thrombopoietin serum concentrations in myelodysplasias. **1998**, 9, 287-90

2

1633 Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. **1998**, 18, 871-7

19

1632 Pleural effusion in chronic myelomonocytic leukemia. **1998**, 99, 34-7

26

1631 Some aspects of morphological and dysplastic changes of the bone marrow in malignant lymphoma. **1998**, 100, 142-6

3

1630 Obstructive uropathy associated with myelomonocytic infiltration of the prostate. **1998**, 51, 340-2

4

1629 Relationship between soluble transferrin receptors in serum and membrane-bound transferrin receptors. **1998**, 99, 8-11

13

1628 Cytogenetic analysis of de novo acute myeloid leukemia with trilineage myelodysplasia in comparison with myelodysplastic syndrome evolving to acute myeloid leukemia. **1998**, 12, 1259-62

1627 Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. **1998**, 13, 91-6

9

1626 Haematological problems in elderly patients: an update. **1998**, 8, 141-154

2

1625 Pathogenetic Aspects of Myelodysplastic Syndromes. **1998**, 3, 119-42

1624 Diagnosis and Management of Anemia in Patients With the Myelodysplastic Syndrome. **1998**, 5, 41-45

1

1623 Fine needle aspiration of extramedullary myeloid cell tumor in myelodysplastic syndrome. A report of three cases. **1999**, 43, 647-51

3

1622 Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. **1999**, 17, 2819-30

117

1621 Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. **1999**, 17, 277-83

9

1620 Clinical features and diagnosis of Fanconi's anemia. **1999**, 319-337

1619 Smoldering acute myelogenous leukemia in the elderly. **1999**, 34, 561-7

9

1618 Childhood ataxic syndromes: experience from Sokoto, north-western Nigeria. **1999**, 45, 111-2

1617 Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines. **1999**, 29, 28-32

12

1616 Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. **2000**, 102, 115-23

50

1615 The impact of breastfeeding practices on respiratory and diarrhoeal disease in infancy: a study from Sri Lanka. **1999**, 45, 115-8

24

1614 Flow-cytometric analysis of leukocyte alkaline phosphatase in myelodysplastic syndromes. **1999**, 102, 89-93

5

1613 Gingival hemorrhage, myelodysplastic syndromes, and acute myeloid leukemia. A case report. **1999**, 70, 1247-53

8

1612 Clinical outcome in three patients with myelodysplastic syndrome showing polyclonal hematopoiesis. **1999**, 101, 46-9

5

1611 Anticardiolipin antibodies in myelodysplastic syndromes. **1999**, 101, 161-2

1610 Ocular extramedullary myeloid cell tumour in children: an Indian study. **1999**, 45, 112-5

3

1609 Storage of iron in bone marrow plasma cells. Ultrastructural characterization, mobilization, and diagnostic significance. **1999**, 101, 7-15

17

1608 The Principles of Clinical Cytogenetics. **1999**,

39

1607 Myelodysplasia. **1999**, 340, 1649-60

411

1606 Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. *British Journal of Haematology*, **1999**, 104, 569-73

4.5 23

1605 Treatment of relapsed AML in children. *British Journal of Haematology*, **1999**, 104, 420-1

4.5 2

1604 The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. *British Journal of Haematology*, **1999**, 104, 730-7

4.5 151

1603 Dendritic cells in chronic myelomonocytic leukaemia. *British Journal of Haematology*, **1999**, 105, 974-85

4.5 31

1602	A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. <i>British Journal of Haematology</i> , 1999 , 106, 1027-32	4.5	90
1601	Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1999 , 107, 844-50	4.5	39
1600	Treatment of relapsed AML in children. <i>British Journal of Haematology</i> , 1999 , 104, 420-421	4.5	
1599	EP2 and EP4 receptor subtypes in human bone marrow stromal cells. <i>British Journal of Haematology</i> , 1999 , 104, 421-2	4.5	3
1598	Successful treatment of acquired myelofibrosis with pure red cell aplasia by cyclosporine. <i>British Journal of Haematology</i> , 1999 , 104, 422-4	4.5	8
1597	'TUNEL' evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient treated with amifostine. <i>British Journal of Haematology</i> , 1999 , 104, 424-5	4.5	6
1596	The use of liposomal amphotericin B in the treatment of neutropenia-associated fungal infections: efficacy and cost-effectiveness. <i>British Journal of Haematology</i> , 1999 , 104, 425-6	4.5	2
1595	Paediatric myelodysplastic syndrome (MDS) and juvenile chronic myelogenous leukaemia (JCML) detected by cytogenetic and FISH techniques. 1999 , 21, 403-6		2
1594	Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. 1999 , 39, 763-71		110
1593	Significance of electron-dense deposits in the mitochondrial matrix of erythroid precursors in aplastic anaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 1999 , 105, 149-154	4.5	14
1592	Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1999 , 105, 141-148	4.5	37
1591	Myelodysplasia and myeloproliferative disorders in childhood: an update. <i>British Journal of Haematology</i> , 1999 , 105, 852-863	4.5	62
1590	Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. 1999 , 13, 44-53		71
1589	Clonality analysis of refractory anemia with ring sideroblasts: simultaneous study of clonality and cytochemistry of bone marrow progenitors. 1999 , 13, 130-4		7
1588	Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. 1999 , 13, 250-7		85
1587	The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. 1999 , 13, 393-9		158
1586	Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). 1999 , 13, 376-85		121
1585	WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. 1999 , 13, 891-900		47

1584	Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. 1999 , 13, 1009-12	28
1583	Vitamin K2 induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation. 1999 , 13, 1399-405	32
1582	Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. 1999 , 13, 1554-63	47
1581	New system for assessing the prognosis of refractory anemia patients. 1999 , 13, 1727-34	17
1580	Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein. 1999 , 18, 3716-24	27
1579	Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. 1999 , 23, 21-5	36
1578	Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. 1999 , 23, 997-1002	14
1577	Leukemias and lymphomas: time trends in the UK, 1984-93. 1999 , 10, 35-42	45
1576	Complete remission of refractory anemia following a single high dose of cyclophosphamide. 1999 , 78, 87-8	8
1575	Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. 1999 , 78, 125-30	31
1574	Idiopathic myelofibrosis in a cat and in three dogs. 1999 , 9, 17-24	10
1573	A strategy for erythropoietin treatment in myelodysplastic syndromes. 1999 , 16, 188-90	
1572	Cytogenetic analysis and RAS mutations in primary myelodysplastic syndromes. 1999 , 111, 124-9	7
1571	Biclonal chromosomal aberrations in a child with myelodysplastic syndrome. 1999 , 108, 13-8	9
1570	Chromosome 11 abnormalities in myelodysplastic syndromes. 1999 , 114, 58-61	12
1569	Myelodysplastic syndrome with atypical eosinophilia in association with ring chromosome 7. A case report. 1999 , 115, 19-22	4
1568	Myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and chronic myeloproliferative disorder (CMPD) in cats. 1999 , 121, 203-16	8
1567	Molecular cytogenetics localizes two new breakpoints on 11q23.3 and 21q11.2 in myelodysplastic syndrome with t(11;21) translocation. 1999 , 24, 199-206	13

1566	Cytogenetic polyclonality in hematologic malignancies. 1999 , 24, 222-229		24
1565	Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual-color fluorescence in situ hybridization and confocal laser scanning microscopy. 1999 , 25, 332-338		15
1564	Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. 1999 , 26, 336-345		86
1563	Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. 1999 , 86, 2006-2013		20
1562	Myelodysplastic syndromes with nephrotic syndrome. <i>American Journal of Hematology</i> , 1999 , 60, 200-4	7.1	15
1561	Loss of maternal allele in a child with myelodysplastic syndrome and monosomy 7. <i>American Journal of Hematology</i> , 1999 , 62, 49-51	7.1	5
1560	The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. 1999 , 34, 443-9		30
1559	Childhood myelodysplastic syndromes in a Brazilian population. 1999 , 16, 347-53		11
1558	Myelodysplastic syndrome with sideroblastic differentiation in a dog. 1999 , 28, 59-63		16
1557	Chronic myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98/HOXA9 fusion. 1999 , 115, 70-2		27
1556	Micronuclei and nuclear abnormalities observed in erythroblasts in myelodysplastic syndromes and in de novo acute leukemia after treatment. 1999 , 101, 32-40		11
1555	Long-term case study of myelodysplastic syndrome in a dog. 1999 , 35, 475-81		12
1554	Protracted Overexposure to a 137Cs Source: II, Clinical Sequelae. 1999 , 81, 91-100		6
1553	Application of the International Prognostic Scoring System for myelodysplastic syndromes. 1999 , 10, 825-9		26
1552	A Patient with Genetic Deletion of Glutathione-S-Transferase T1 and M1 Who Developed Non-Small-Cell Lung Cancer and Myelodysplastic Syndromes. 1999 , 318, 424-427		
1551	De novo acute myelogenous leukemia with trilineage myelodysplasia associated with t(8;21)(q22;q22). <i>Internal Medicine</i> , 1999 , 38, 607-11	1.1	3
1550	Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome. <i>Internal Medicine</i> , 2000 , 39, 412-5	1.1	20
1549	Chronic myelomonocytic leukemia in a cat. 2000 , 62, 195-7		10

1548	New Aspects of the Treatment of Patients with Low-Risk Myelodysplastic Syndromes. 2000 , 23, 12-16			1
1547	Myelodysplastic Syndromes in Childhood. 2000 , 23, 18-24			2
1546	Chronic Myelomonocytic Leukemia with t(1;3)(p3 6;q2 1) and a Synchronous Gastric Cancer. 2000 , 319, 258-260			
1545	Immature myeloid precursors in chronic neutrophilic dermatosis associated with myelodysplastic syndrome. 2000 , 22, 429-33			27
1544	Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma. 2000 , 88, 1939-1944			36
1543	Utility of blasts with a clear halo around the nucleolus as a predictive indicator for disease progression in patients with myelodysplastic syndromes and aplastic anemia. 2000 , 22, 275-80			
1542	5q- syndrome presenting chronic myeloproliferative disorders-like manifestation: a case report. <i>American Journal of Hematology</i> , 2000 , 64, 120-3	7.1		5
1541	Concurrent Langerhans cell histiocytosis and myelodysplasia in children. 2000 , 35, 421-5			24
1540	Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. <i>British Journal of Haematology</i> , 2000 , 108, 582-91	4.5		32
1539	Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. <i>British Journal of Haematology</i> , 2000 , 109, 367-75	4.5		80
1538	Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. <i>British Journal of Haematology</i> , 2000 , 110, 577-83	4.5		157
1537	Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2000 , 110, 584-90	4.5		32
1536	Risk of colorectal cancer in patients with hematologic disease. 2000 , 15, 1272-1276			1
1535	Stem cell transplantation for a myelodysplastic syndrome in children. 2000 , 5, 43-47			
1534	Bilateral necrotizing scleritis and blindness in the myelodysplastic syndrome presumably due to relapsing polychondritis. 2000 , 78, 228-31			13
1533	Oral findings in three different groups of immunocompromised patients. 2000 , 29, 153-8			36
1532	Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. 2000 , 14, 636-41			45
1531	Allelotype analysis of the myelodysplastic syndrome. 2000 , 14, 805-10			13

1530	An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. 2000 , 14, 786-91	58
1529	Increase therapy-related leukemia secondary to breast cancer. 2000 , 14, 1014-7	47
1528	Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study. 2000 , 14, 1583-8	6
1527	Elevated MLF1 expression correlates with malignant progression from myelodysplastic syndrome. 2000 , 14, 1757-65	44
1526	Colony-forming unit-megakaryocyte (CFU-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. 2000 , 14, 1751-6	9
1525	Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. 2000 , 14, 2045-51	38
1524	CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes. 2000 , 64, 71-9	23
1523	Effect of biscochlorine alkaloids, prednisolone and ascorbic acid on myelodysplastic syndrome with pancytopenia: a case report. 2000 , 64, 61-5	
1522	Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. 2000 , 24, 839-48	62
1521	Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors. 2000 , 24, 999-1008	1
1520	Reciprocal translocation (3;5)(q26;q22) and possible BCHE gene involvement in an unusual myelogenous disorder with both myeloproliferative and dysplastic features. 2000 , 121, 133-8	2
1519	Myelodysplastic syndrome associated with monosomy 7 in a child with Bloom syndrome. 2000 , 116, 44-6	23
1518	Fanconi anemia: myelodysplasia as a predictor of outcome. 2000 , 117, 125-31	84
1517	Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. 2000 , 83, 91-4	43
1516	Bone marrow transplantation for myelodysplasia. 2000 , 14, 63-77	34
1515	Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia. 2000 , 14, 182-9	8
1514	Myelodysplastic syndromes. 2000 , 1, 63-9	7
1513	Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia. 2000 , 2, 140-3	5

1512	Specific cutaneous infiltrate caused by <i>Staphylococcus aureus</i> in a patient with chronic myelomonocytic leukemia. 2000 , 79, 402-4	3
1511	Leukemic hypopyon in acute myelogenous leukemia. 2000 , 79, 455-8	18
1510	Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML). 2000 , 79, 30-5	24
1509	Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. 2000 , 79, 255-8	19
1508	[Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis]. 2000 , 21, 1-15	11
1507	The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. 2000 , 96, 3932-3938	267
1506	Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. 2000 , 96, 2012-2021	193
1505	The chromosomes can tell you what they're made of. 2000 , 96, 2021-2021	2
1504	Defective megakaryocytic development in myelodysplastic syndromes. 2000 , 38, 13-9	23
1503	Prevalence and survival of myelodysplastic syndrome of the refractory anemia type in hospitalized cognitively different geriatric patients. 2000 , 46, 323-7	10
1502	S. 2000 , 781-886	
1501	Diagnostic flow cytometry in hematologic malignancies. 2001 , 55, 179-215	
1500	NEW PERSPECTIVES ON THE DIFFERENTIATION OF APLASTIC ANEMIA AND MDS IN CHILDREN. 2000 , 19, 261-267	
1499	Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. 2000 , 40, 67-77	55
1498	Achievements in Understanding and Treatment of Myelodysplastic Syndromes. 2000 , 2000, 110-132	16
1497	Treatment-associated leukemia following testicular cancer. 2000 , 92, 1165-71	191
1496	Comparative genomic hybridization study of de novo myeloid neoplasia. 2000 , 104, 25-30	10
1495	Chronic myelomonocytic leukemia developed 2 years after the onset of immune thrombocytopenic purpura like syndrome. 2000 , 30, 221-4	3

1494	Increased prevalence of GSTM(1) null genotype in patients with myelodysplastic syndrome: a case-control study. 2000 , 104, 169-73	16
1493	Myelodysplasia or myeloneoplasia: thoughts on the nosology of clonal myeloid diseases. 2000 , 26, 572-81	25
1492	Increased HbF levels in dyserythropoiesis. 2000 , 291, 83-7	7
1491	Red cells II: acquired anaemias and polycythaemia. 2000 , 355, 1260-8	26
1490	Primary Myelodysplastic Syndromes of Dogs: A Report of 12 Cases. 2000 , 14, 491-494	20
1489	Molecular models of benzene leukemogenesis. 2000 , 61, 391-7	12
1488	Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro. 2000 , 39, 173-84	9
1487	SIGNIFICANCE OF MONOSOMY 7 IN MYELOID LEUKEMIAS IN CHILDREN. 2000 , 19, 235-250	0
1486	Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. 2000 , 18, 112-9	18
1485	In vitro proliferation and differentiation of megakaryocytic progenitors in patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria, and the myelodysplastic syndromes. 2000 , 18, 428-34	13
1484	The cytogenetics of myelodysplastic syndromes. 2001 , 14, 479-95	59
1483	Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. 2001 , 97, 1427-34	292
1482	Treatment of myelodysplastic syndromes. 2001 , 6, 74-9	2
1481	Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. 2001 , 7, 163-70	20
1480	Cytologic evaluation of primary and secondary myelodysplastic syndromes in the dog. 2001 , 30, 67-75	32
1479	Hematologic Abnormalities and Outcome of 16 Cats with Myelodysplastic Syndromes. 2001 , 15, 471-477	38
1478	Síndromes mielodisplásicos. 2001 , 8, 2749-2754	
1477	[Incidence and survival of leukemias according to the different histologic subsets, in Tarragona, Spain, between 1980-1994]. 2001 , 116, 174-8	3

1476	Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis--Behçet's syndrome. 2001 , 42, 115-21		62
1475	Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI. 2001 , 19, 3794		9
1474	Full-impact medicine. 2001 , 19, 3793-4		1
1473	Validation of the ucla integrated staging system for patients with renal cell carcinoma. 2001 , 19, 3792-3		47
1472	Myelodysplastic syndromes: histopathology as prognostic factor. 2001 , 23, 63		
1471	Myelodysplastic syndrome accompanied by Addison's disease and multiple autoimmune phenomena: steroid therapy resolved cytopenias and all immune disorders. <i>Internal Medicine</i> , 2001 , 40, 1041-4	1.1	11
1470	Immune pathology of myelodysplastic syndromes. <i>Internal Medicine</i> , 2001 , 40, 985-6	1.1	
1469	Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. 2001 , 98, 2935-41		101
1468	Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. 2001 , 98, 3784-92		46
1467	Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. 2001 , 98, 422-7		129
1466	Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. 2001 , 98, 495-7		37
1465	Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. 2001 , 98, 958-65		272
1464	Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. 2001 , 98, 979-87		238
1463	Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. 2001 , 98, 1914-21		31
1462	Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. 2001 , 98, 2326-31		130
1461	[Place of hematopoietic stem cell transplantation in the treatment of myelodysplastic syndromes]. 2001 , 96, 135-43		
1460	Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome. 2001 , 80, 53-7		3
1459	Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. 2001 , 80, 272-7		27

1458	Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. 2001 , 80, 330-3		34
1457	Evolving treatment options of myelodysplastic syndromes. 2001 , 80, 499-509		8
1456	Immunosuppressive therapy for patients with refractory anemia. 2001 , 80, 634-8		35
1455	Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor: a multicenter study. 2001 , 74, 144-6		6
1454	Proliferative capacity of single isolated CD34+ hematopoietic stem/progenitor cells in paroxysmal nocturnal hemoglobinuria. 2001 , 74, 42-52		1
1453	Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. 2001 , 73, 405-410		67
1452	Bone marrow colony-forming unit assay in cats with naturally occurring myelodysplastic syndromes. 2001 , 73, 453-456		5
1451	Reduced CD43 expression on the neutrophils of MDS patients correlates with an activated phenotype of these cells. 2001 , 73, 483-491		5
1450	Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. <i>British Journal of Haematology</i> , 2001 , 112, 392-6	4.5	28
1449	Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. <i>British Journal of Haematology</i> , 2001 , 112, 927-35	4.5	61
1448	Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2001 , 115, 25-33	4.5	63
1447	International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2001 , 115, 309-12	4.5	72
1446	Spherocytosis preceding the development of myelodysplasia. 2001 , 23, 249-51		3
1445	Hyperdiploid karyotype in a childhood MDS patient. 2001 , 23, 255-8		3
1444	Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. 2001 , 31, 894-901		9
1443	Primary myelodysplasia: management and outcome at 3 years in 45 patients age 65 and older. 2001 , 49, 1358-60		2
1442	Re-evaluation of refractory anemia with excess blasts in transformation. 2001 , 25, 933-9		13
1441	Increased peripheral stem cell pool in MDS: an indication of disease progression?. 2001 , 25, 955-9		12

1440	Management of high-risk myelodysplastic syndromes. 2001 , 40, 215-28		6
1439	Myelodysplastic syndrome: review of the cytogenetic and molecular data. 2001 , 40, 229-38		42
1438	The spleen as a diagnostic specimen: a review of 10 years' experience at two tertiary care institutions. 2001 , 91, 2001-9		93
1437	High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. 2001 , 92, 1999-2015		70
1436	Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study. <i>American Journal of Hematology</i> , 2001 , 66, 23-7	7.1	8
1435	Monocytic leukemia cutis diagnosed simultaneously with refractory anemia with monocytosis: a case report. <i>American Journal of Hematology</i> , 2001 , 66, 120-2	7.1	2
1434	Successful treatment of refractory anemia by high-dose methylprednisolone associated with an increment in CD68-positive cells in bone marrow. <i>American Journal of Hematology</i> , 2001 , 66, 80-4	7.1	2
1433	DNA content of granulocytes, monocytes, and lymphocytes in the bone marrow smears of patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2001 , 67, 112-8	7.1	
1432	Morphological diagnoses of the Japan adult leukemia study group acute myeloid leukemia protocols: central review. 2001 , 73, 93-9		15
1431	Tyrosine phosphorylation of proteins in primary human myeloid leukemic cells stimulated by macrophage colony-stimulating factor: analysis by disease type and comparison with normal human hematopoietic cells. 2001 , 73, 100-7		1
1430	Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis. 2001 , 20, 132-5		22
1429	Glomerular involvement in myelodysplastic syndromes. 2001 , 16, 1053-7		10
1428	A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. 2001 , 28, 643-7		42
1427	Incidence of hematological malignancies in Martinique, French West Indies, overrepresentation of multiple myeloma and adult T cell leukemia/lymphoma. 2001 , 15, 828-31		16
1426	Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. 2001 , 15, 950-3		38
1425	Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. 2001 , 15, 1111-7		50
1424	Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. 2001 , 15, 1713-20		80
1423	Predicting the presence or absence of ringed sideroblasts in patients suspected of having a myelodysplastic syndrome and increased iron stores: a simple observation. 2001 , 15, 1793-5		1

1422	Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 2001 , 15, 1841-7	77
1421	Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. 2001 , 15, 1878-84	28
1420	Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. <i>British Journal of Haematology</i> , 2001 , 114, 349-354-5	2
1419	Myelodysplastic features in patients with long-term HIV infection and haemophilia. 2001 , 7, 47-52	1
1418	Trisomy 8 and monosomy 7 detected in bone marrow using primed in situ labeling, fluorescence in situ hybridization, and conventional cytogenetic analyses. A study of 54 cases with hematological disorders. 2001 , 125, 30-40	20
1417	Acute myeloid leukemia with concomitant trisomies 4 and 10: a distinctive form of myeloid leukemia?. 2001 , 127, 74-6	5
1416	Therapy-related refractory anemia with ringed sideroblasts in chronic lymphocytic leukemia. involvement of 3q21 region. 2001 , 129, 43-6	4
1415	The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. 2001 , 130, 160-5	48
1414	Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. 2001 , 25, 333-8	54
1413	Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. 2001 , 25, 287-94	30
1412	Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. 2001 , 25, 385-93	33
1411	Dysplastic versus proliferative CMML--a retrospective analysis of 91 patients from a single institution. 2001 , 25, 741-7	46
1410	Diagnostic criteria and classification of mastocytosis: a consensus proposal. 2001 , 25, 603-25	871
1409	Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. 2001 , 25, 595-602	57
1408	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. 2001 , 25, 529-36	184
1407	Myelodysplasia with fibrosis: a distinct entity?. 2001 , 25, 829-38	44
1406	Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. 2001 , 31, 119-26	59
1405	Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. 2001 , 66, 31-6	7

1404	Decreased amount of mpl and reduced expression of glycoprotein IIb/IIIa and glycoprotein Ib on platelets from patients with refractory anemia: analysis by a non-isotopic quantitative ligand binding assay and immunofluorescence. 2001 , 66, 245-52	4
1403	Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. <i>British Journal of Haematology</i> , 2001 , 114, 349-57 ^{4,5}	207
1402	Predominant fatty variant of myofibroblastoma of breast. 2001 , 54, 568-9	9
1401	Immunophenotyping of Acute Leukaemias. Immunophänotypisierung akuter Leukämien. 2001 , 25, 512-532	
1400	Guillain-Barré syndrome following herpes zoster in a patient with systemic sclerosis. 2001 , 11, 251-4	3
1399	Identification and treatment of anaemia in older patients. 2001 , 11, 5-19	
1398	Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). 2001 , 6 Suppl 5, 8-14	86
1397	Myelodysplasia-like syndrome and end-stage liver disease: report of 2 cases. 2001 , 105, 100-2	0
1396	Effect of short-course, high-dose steroid therapy in a child with myelodysplastic syndrome. 2001 , 18, 525-9	2
1395	Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. 2001 , 27, 589-92	25
1394	Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. 2002 , 11, 119-25	60
1393	The World Health Organization (WHO) classification of the myeloid neoplasms. 2002 , 100, 2292-302	1637
1392	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. 2002 , 100, 1201-7	253
1391	Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. 2002 , 32, 169-73	8
1390	Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia. 2002 , 13 Suppl 1, 40-3	4
1389	Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. 2002 , 108, 139-43	20
1388	Levels of circulating endothelial adhesion molecules in patients with myelodysplastic syndromes. 2002 , 20, 167	4
1387	Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. 2002 , 63, 64-9	58

1386	A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. 2002 , 24, 596-605	42
1385	Spurious dyserythropoiesis. 2002 , 117, 57-9	14
1384	Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum. 2002 , 43, 761-5	10
1383	Combination of mitoxantrone and etoposide in the Treatment of Advanced Myelodysplastic Syndrome/Secondary Acute Myeloid Leukemia - a Multicenter Phase II Study. 2002 , 23, 57-61	
1382	Dynamische MRT der Lendenwirbelsäule zur Beurteilung der Mikrozirkulation unter anti-angiogenetischer Therapie bei Patienten mit Myelodysplastischen Syndromen. 2002 , 174, 58-64	0
1381	High incidence of point mutations of p53 suppressor oncogene in patients with myelodysplastic syndrome among atomic-bomb survivors: a 10-year follow-up. 2002 , 16, 154-6	10
1380	Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. 2002 , 16, 623-31	18
1379	Myelodysplastic syndromes. 2002 , 2002, 136-61	107
1378	Thalidomide for the treatment of patients with myelodysplastic syndromes. 2002 , 16, 1-6	125
1377	Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. 2002 , 16, 162-4	83
1376	Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome. 2002 , 16, 165-9	3
1375	[Dynamic MRI of the lumbar spine for the evaluation of microcirculation during anti-angiogenetic therapy in patients with myelodysplastic syndromes]. 2002 , 174, 164-9	7
1374	De novo appearance of t(7;13)(q10;q33) in the leukemic phase of myelodysplastic syndrome: a case report. 2002 , 32, 35-6	2
1373	Prospective Study of 90 Children Requiring Treatment for Juvenile Myelomonocytic Leukemia or Myelodysplastic Syndrome: A Report From the Children's Cancer Group. 2002 , 20, 434-440	32
1372	Die neue WHO-Klassifikation zur Einteilung der akuten myeloischen Leukämien (AML): Vorteile und Probleme im Vergleich zur FAB (French-American-British)-Klassifikation/The New WHO Classification for Acute Myeloid Leukemias: Comparison to the FAB Classification. 2002 , 26, 19-22	
1371	Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. 2002 , 13, 450-9	51
1370	New approaches to the treatment of myelodysplasia. 2002 , 7 Suppl 1, 39-49	48
1369	Myelodysplastic syndrome following therapy for brain tumor--two case reports. 2002 , 42, 170-4	3

1368	Atypical cellular disorders. 2002 , 2002, 297-314	23
1367	A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. 2002 , 24, 343-52	15
1366	Myelodysplasia and the acute myeloid leukaemias. 2002 , 7, 325-38	1
1365	Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. 2002 , 100, 238-45	355
1364	Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. 2002 , 100, 427-34	63
1363	Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. 2002 , 99, 4370-8	124
1362	Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. 2002 , 99, 822-4	110
1361	Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. 2002 , 99, 840-9	304
1360	Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. 2002 , 99, 1578-84	41
1359	Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. 2002 , 99, 3074-5	21
1358	Mutations of Chk2 in primary hematopoietic neoplasms. 2002 , 99, 3075-7	32
1357	Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. 2002 , 99, 4638-41	213
1356	Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. 2002 , 100, 3869-76	153
1355	Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. 2002 , 100, 3887-96	155
1354	Immunophenotypic clustering of myelodysplastic syndromes. 2002 , 100, 2349-56	97
1353	Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. 2002 , 100, 3897-902	168
1352	Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). <i>Internal Medicine</i> , 2002 , 41, 1183-7	1.1 32
1351	Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. 2002 , 137, 156-63	164

1350	Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia. 2002 , 20, 154-62	8
1349	Tuberculosis in patients with myelodysplastic syndromes. 2002 , 57, 408-14	6
1348	Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. 2002 , 100, 786-90	150
1347	Myelodysplastic Syndrome. 2002 , 1, 301-311	1
1346	Apoptosis and prognostic factors in myelodysplastic syndromes. 2002 , 43, 257-60	12
1345	Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. 2002 , 43, 2083-92	120
1344	Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. 2002 , 43, 275-80	24
1343	Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. 2002 , 43, 1409-14	16
1342	Human Cell Culture. 2002 ,	2
1341	Myelodysplastic syndrome overview. 2002 , 39, 18-25	42
1340	Thalidomide in myelodysplastic syndromes. 2002 , 56, 20-30	7
1339	[New WHO classification of myelodysplastic syndromes. The consequences]. 2002 , 50, 278-82	3
1338	Acute myeloid leukemia and related conditions. 2002 , 16, 301-19	7
1337	Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. 2002 , 77, 1169-75	30
1336	Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. 2002 , 20, 434-40	79
1335	Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. 2002 , 132, 97-101	38
1334	Refractory anemia with ring sideroblasts associated with i(17q) and mutation of the TP53 gene. 2002 , 136, 86-9	5
1333	Aplastic anemia evolving into overt myelodysplastic syndrome/acute myeloid leukemia with t(3;5)(p25;q31). 2002 , 137, 91-4	4

1332	Cytogenetic survey of 117 Tunisian patients with de novo myelodysplastic syndrome. 2002 , 45, 131-5		1
1331	Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation. 2002 , 68, 54-63		15
1330	Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. 2002 , 68, 180-5		37
1329	Die neue WHO-Klassifikation zur Einteilung der akuten myeloischen Leukämien (AML): Vorteile und Probleme im Vergleich zur FAB (French-American-British)-Klassifikation. 2002 , 26, 19-22		
1328	Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2002 , 70, 115-25	7.1	46
1327	Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2002 , 71, 166-71	7.1	40
1326	Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. 2002 , 94, 1739-46		283
1325	Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. 2002 , 95, 1673-84		63
1324	Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis. 2002 , 50, 225-30		11
1323	New human myelodysplastic cell line, TER-3: G-CSF specific downregulation of Ca ²⁺ /calmodulin-dependent protein kinase IV. 2002 , 191, 183-90		3
1322	Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndrome: identification of new amplification regions by fluorescence in situ hybridization and spectral karyotyping. 2002 , 34, 42-7		53
1321	Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. 2002 , 33, 60-72		88
1320	Two independent clones in myelodysplastic syndrome following treatment of acute myeloid leukemia. 2002 , 75, 182-6		7
1319	Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. 2002 , 75, 289-97		68
1318	Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome. 2002 , 75, 302-4		5
1317	Pure red cell aplasia developing into myeloproliferation with myelodysplasia and subsequent leukemia after cyclosporin A therapy. 2002 , 75, 514-8		5
1316	Histologic verification of leukemia, myelodysplasia, and multiple myeloma diagnoses in patients in Ukraine, 1987-1998. 2002 , 76, 55-60		12
1315	Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. 2002 , 76, 272-8		31

1314	[Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy]. 2002 , 42, 222-30		7
1313	[Myelodysplastic syndromes. Diagnosis and therapeutic strategies]. 2002 , 97, 666-76		10
1312	Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. 2002 , 81, 16-9		19
1311	Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. 2002 , 81, 11-5		22
1310	Evaluating the prognosis of patients with myelodysplastic syndromes. 2002 , 81, 485-97		30
1309	Assessment of growth and differentiation processes in myelodysplastic syndromes by PCR analysis of Galpha16 and 5'-lipoxygenase. 2002 , 81, 632-40		2
1308	In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF). 2002 , 81, 695-700		4
1307	Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. 2002 , 128, 497-502		20
1306	Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 116, 716-24	4.5	63
1305	Symposium 6B: Unusual features of the bone marrow. 2002 , 41, 93-112		1
1304	A case of S ^c zary's syndrome associated with granulomatous lesions, myelodysplastic syndrome and transformation into CD30-positive large-cell pleomorphic lymphoma. 2002 , 147, 582-6		23
1303	Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia. <i>British Journal of Haematology</i> , 2002 , 116, 151-4	4.5	16
1302	Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. <i>British Journal of Haematology</i> , 2002 , 117, 33-9	4.5	39
1301	Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor. <i>British Journal of Haematology</i> , 2002 , 118, 181-8	4.5	18
1300	Sex ratios and the risks of haematological malignancies. <i>British Journal of Haematology</i> , 2002 , 118, 1071-7	4.5	84
1299	Prognosis of myelodysplastic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. <i>British Journal of Haematology</i> , 2002 , 119, 87-96	4.5	11
1298	rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. <i>British Journal of Haematology</i> , 2002 , 119, 652-9	4.5	28
1297	Does isochromosome 7q mandate bone marrow transplant in children with Shwachman-Diamond syndrome?. <i>British Journal of Haematology</i> , 2002 , 119, 1062-9	4.5	38

1296	Detection of small numbers of cells characteristic for haematological disorders in peripheral blood (the deep diff). 2002 , 24, 73-80	2
1295	Megakaryoblastic transformation of chronic myelomonocytic leukemia presenting with severe bone pain. 2002 , 2, 105-109	
1294	Classification des leuc ^m ies aigu ^m es : nouvelles propositions de l'oms (Organisation Mondiale de la Sant ^e). 2002 , 2002, 19-24	4
1293	Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. 2002 , 26, 249-54	43
1292	Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. 2002 , 26, 721-4	38
1291	Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. 2002 , 26, 821-4	46
1290	Bone marrow transplantation for myelodysplastic syndrome--who? when? and which?. 2002 , 30, 199-206	15
1289	Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. 2002 , 16, 1615-21	52
1288	More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. 2002 , 16, 2249-52	19
1287	Monoclonal constitution of neutrophils detected by PCR-based human androgen receptor gene assay in a subset of idiopathic thrombocytopenic purpura patients. 2002 , 26, 825-30	9
1286	Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. 2002 , 26, 993-6	53
1285	Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes. 2002 , 19, 249-59	14
1284	Oxidative stress and the myelodysplastic syndromes. 2003 , 77, 342-50	80
1283	Successful aortic valve replacement in severe pancytopenia related to myelodysplastic syndrome. 2003 , 51, 77-80	6
1282	Successful replacement of aortic root with valve-sparing technique and proximal arch in a patient with myelodysplastic syndrome. 2003 , 51, 322-5	5
1281	Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). 2003 , 115, 515-36	4
1280	Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies. 2003 , 115, 537-46	12
1279	Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes. 2003 , 82, 271-7	11

1278	Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. 2003 , 82, 336-42		88
1277	Meningeal involvement of chronic myelomonocytic leukemia. 2003 , 250, 993-4		6
1276	Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. 2003 , 129, 485-91		12
1275	Uneventful outcome of unrelated hematopoietic stem cell transplantation in a patient with leukemic transformation of Kostmann syndrome and long-lasting invasive pulmonary mycosis. 2003 , 70, 322-5		12
1274	Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. 2003 , 31, 89-97		7
1273	Reduced expression of flavocytochrome b558, a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia. 2003 , 31, 752-9		10
1272	A unique clone involving multiple structural chromosome rearrangements in a myelodysplastic syndrome case. 2003 , 140, 138-44		5
1271	Is monosomy 5 an uncommon aberration? Fluorescence in situ hybridization reveals translocations and deletions in myelodysplastic syndromes or acute myelocytic leukemia. 2003 , 142, 107-14		16
1270	Apoptotic rate in patients with myelodysplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines. <i>Journal of Cellular and Molecular Medicine</i> , 2003 , 7, 313-21	5.6	3
1269	Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasia. <i>American Journal of Hematology</i> , 2003 , 74, 9-16	7.1	15
1268	The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. 2003 , 27, 95-120		125
1267	Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. 2003 , 27, 235-42		54
1266	Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. 2003 , 27, 775-82		25
1265	7th International Symposium on Myelodysplastic. 2003 , 27, 1-123		2
1264	Disordered hematopoiesis and myelodysplasia in the elderly. 2003 , 51, S22-6		34
1263	Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2003 , 120, 187-200	4.5	211
1262	A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. <i>British Journal of Haematology</i> , 2003 , 120, 679-84	4.5	108
1261	Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. <i>British Journal of Haematology</i> , 2003 , 121, 758-67	4.5	103

1260	Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. <i>British Journal of Haematology</i> , 2003 , 122, 226-30	4.5	31
1259	The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. <i>British Journal of Haematology</i> , 2003 , 123, 81-9	4.5	15
1258	Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. 2003 , 32, 1071-5		11
1257	A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. 2003 , 17, 277-82		346
1256	Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. 2003 , 17, 305-13		87
1255	The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. 2003 , 17, 343-9		35
1254	Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). 2003 , 17, 910-8		53
1253	Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. 2003 , 17, 1200-2		23
1252	The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). 2003 , 17, 859-68		34
1251	Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. 2003 , 17, 1600-4		62
1250	No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. 2003 , 17, 1827-33		30
1249	DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia. 2003 , 17, 1990-7		20
1248	Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. 2003 , 17, 2101-6		67
1247	A severe hepatic disorder with myelodysplastic syndrome, treated with cytarabine ocfosfate, in a dog. 2003 , 81, 47-9		3
1246	Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. 2003 , 27, 305-12		32
1245	Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. 2003 , 27, 397-404		32
1244	MDS--new classification, new problem?. 2003 , 27, 567-9		4
1243	Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. 2003 , 78, 981-90		2

1242	Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. 2003 , 9, 753-9	29
1241	Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. 2003 , 199, 185-92	27
1240	New insights into the physiology and treatment of acquired myelodysplastic syndromes and aplastic pancytopenia. 2003 , 33, 1317-34	13
1239	[Biologic and clinical relevance of cytogenetic analysis in primary myelodysplastic syndromes]. 2003 , 51, 346-55	2
1238	Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. 2003 , 20, 154-79	15
1237	Pathology teach and tell: congenital myelodysplastic syndrome with extensive hepatic fibrosis. 2003 , 22, 265-70	
1236	Chronic myelomonocytic leukemia coexisting with B-cell chronic lymphocytic leukemia. 2003 , 44, 2001-8	8
1235	Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. 2003 , 44, 915-22	41
1234	Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. 2003 , 21, 1988-95	125
1233	Diagnostic Significance of Detecting Dysgranulopoiesis in Chronic Myeloid Leukemia. 2003 , 120, 778-784	8
1232	Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. 2003 , 44, 1339-46	25
1231	Cancer Cytogenetics. 2003 ,	10
1230	Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. 2003 , 21, 273-82	48
1229	Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. 2003 , 21, 256-65	139
1228	Understanding the pathogenesis of myelodysplastic syndromes. 2003 , 4, 303-9	26
1227	Immunosuppressive treatments for myelodysplastic syndromes. 2003 , 44, 593-604	17
1226	Myelodysplasia: differentiating neoplastic from nonneoplastic syndromes of ineffective hematopoiesis in dogs. 2003 , 31 Suppl, 44-8	10
1225	Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. 2003 , 44, 653-8	24

1224	The myeloid disorders: background. 2003 , 220, 23-42	1
1223	Behçet's disease accompanied by myelodysplastic syndrome with trisomy 8: two case reports and a review of 15 Japanese cases. 2003 , 13, 90-4	8
1222	The evolution of juvenile myelomonocytic leukemia in a female patient with paternally inherited neurofibromatosis type 1. 2003 , 25, 145-7	4
1221	Diagnostic significance of detecting dysgranulopoiesis in chronic myeloid leukemia. 2003 , 120, 778-84	2
1220	Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders. 2003 , 78, 981-990	15
1219	cDNA microarray analysis reveals an overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. 2003 , 366, 103-13	17
1218	Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. 2003 , 101, 1080-6	106
1217	Mitochondrial DNA mutations in patients with myelodysplastic syndromes. 2003 , 101, 3118-25	68
1216	Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. 2003 , 102, 394-403	269
1215	Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). 2003 , 102, 1622-5	25
1214	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. 2003 , 102, 4527-34	117
1213	Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. 2003 , 102, 1997-2003	122
1212	Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. 2003 , 101, 4711-3	69
1211	Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. 2003 , 102, 1866-8	31
1210	Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia. 2003 , 101, 1172-80	47
1209	Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. 2003 , 101, 3386-90	73
1208	Unusual skin lesions in chronic myelomonocytic leukemia. 2003 , 96, 681-4	6
1207	Myelodysplastic syndromes. 2003 , 120 Suppl, S25-37	

1206	Classification, treatment goals, and management principles for myelodysplastic syndromes. 2004 , 11, 3-6	3
1205	Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. 2004 , 122, 166-71	47
1204	Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?. 2004 , 45, 1531-8	16
1203	Myelodysplastic syndromes. 2004 , 2004, 297-317	93
1202	Myelodysplastic syndromes. 2004 , 5, 1-8	45
1201	Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. 2004 , 45, 2409-17	25
1200	Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism. 2004 , 45, 1285-7	7
1199	Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. 2004 , 63, 578-82	35
1198	FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. 2004 , 112, 68-78	61
1197	The 5q- syndrome. 2004 , 9, 271-7	60
1196	Strategies for the laboratory diagnosis of some common causes of anaemia in elderly patients. 2004 , 50, 49-56	22
1195	CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. 2004 , 10, 7599-606	27
1194	Models of granulocyte DNA structure are highly predictive of myelodysplastic syndrome. 2004 , 101, 5008-11	14
1193	Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. 2004 , 172, 1960-9	57
1192	Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. 2004 , 22, 1287-92	124
1191	Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. 2004 , 43, 626-32	81
1190	Differentiation of acute myeloid leukemia from B- and T-lineage acute lymphoid leukemias by real-time quantitative reverse transcription-PCR of lineage marker mRNAs. 2004 , 50, 1165-73	9
1189	Disturbed granulocyte macrophage-colony stimulating factor priming of phosphatidylinositol 3,4,5-trisphosphate accumulation and Rac activation in fMLP-stimulated neutrophils from patients with myelodysplasia. 2004 , 76, 254-62	11

1188	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. <i>British Journal of Haematology</i> , 2004 , 125, 203-12	4.5	22
1187	Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. <i>British Journal of Haematology</i> , 2004 , 125, 576-83	4.5	65
1186	Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. <i>British Journal of Haematology</i> , 2004 , 126, 133-8	4.5	177
1185	Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. 2004 , 34, 690-700		71
1184	Isolated PACNS-like presentation of a systemic vasculitis complicating a myelodysplastic syndrome. 2004 , 255, 674-9		7
1183	Monitoring treatment efficiency in MDS at the molecular level; possibilities now and in the future. 2004 , 28, 101-8		8
1182	Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. 2004 , 33, 531-4		45
1181	Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. 2004 , 33, 805-14		58
1180	Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. 2004 , 18, 113-9		163
1179	A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. 2004 , 18, 460-5		116
1178	Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. 2004 , 18, 466-75		126
1177	Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. 2004 , 18, 1108-14		28
1176	Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes. 2004 , 18, 1451-6		43
1175	Clinical and morphological features of paediatric myelodysplastic syndromes: a review of 34 cases. 2004 , 93, 1015-23		15
1174	Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. 2004 , 73, 17-24		9
1173	Clinical, haematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in a single institute. 2004 , 73, 93-7		15
1172	Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. 2004 , 73, 351-8		27
1171	Targeted therapies in myeloid leukemia. 2004 , 14, 41-62		39

1170	Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. 2004 , 148, 29-34		31
1169	High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. 2004 , 32, 435-40		30
1168	Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. 2004 , 152, 29-41		35
1167	Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. 2004 , 21, 325-31		16
1166	Long-term survivors in myelodysplastic syndromes: clinical and biological characteristics. 2004 , 21, 333-8		3
1165	Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2004 , 125, 709-19	4.5	26
1164	Possibility of the diagnosis of subacute myeloid leukemia for a group of patients with trisomy 8: a report of 34 cases. 2004 , 80, 159-63		
1163	Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. 2004 , 80, 140-5		35
1162	Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. 2004 , 35, 857-63		12
1161	High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival. 2004 , 83, 9-13		17
1160	Classification of refractory anemia. 2004 , 28, 213; discussion 215		
1159	Genomic instability in bone marrow failure syndromes. <i>American Journal of Hematology</i> , 2004 , 76, 220-47.1		16
1158	Centrosome amplification and aneuploidy in bone marrow failure patients. 2004 , 40, 329-33		13
1157	Novel therapies for myelodysplastic syndromes. 2004 , 101, 226-41		41
1156	Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. 2004 , 101, 989-98		36
1155	Immunophenotyping of acute leukemias and myelodysplastic syndromes. 2004 , 58, 62-71		66
1154	Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence. <i>Hematological Oncology</i> , 2004 , 22, 91-109	1.3	10
1153	Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. 2004 , 28 Suppl 1, S47-52		22

1152	Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. 2004 , 28, 551-7	16
1151	Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. 2004 , 28, 579-86	87
1150	Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. 2004 , 28, 587-94	51
1149	Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?. 2004 , 28, 1013-21	59
1148	Overexpression of delta-like (Dlk) in a subset of myelodysplastic syndrome bone marrow trephines. 2004 , 28, 1081-3	18
1147	Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes. 2004 , 28, 1171-5	13
1146	Evaluation of temozolomide in patients with myelodysplastic syndrome. 2004 , 45, 1209-14	3
1145	Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. 2004 , 45, 301-8	14
1144	Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?. 2004 , 28, 1013-1013	
1143	[Applications of molecular biology to care of patients with malignant hematological disease]. 2004 , 62, 401-20	1
1142	Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. 2004 , 114, 28-33	18
1141	Risk assessment in chronic myelomonocytic leukemia (CMML). 2004 , 45, 1311-8	106
1140	The World Health Organization classification of myeloproliferative and myelodysplastic syndromes. 2004 , 10, 394-403	3
1139	A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system. 2004 , 113, 109-16	3
1138	Accumulation of homoplasmic mtDNA point mutations in erythroblasts isolated from the bone marrow of patients with refractory anemia with ring sideroblasts (RARS). 2004 , 4, 321-9	2
1137	[Disease associations in 250 patients with temporal (giant cell) arteritis]. 2004 , 33, 1304-12	11
1136	Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. 2004 , 41, 6-12	51
1135	State of the science for myelodysplastic syndrome: prognosis and promise of new therapies. 2004 , 17, 535-541	2

1134	Pathobiology, classification, and diagnosis of myelodysplastic syndrome. 2004 , 17, 543-557	48
1133	Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. 2004 , 17, 573-584	5
1132	Apoptosis susceptibility and cell-cycle distribution in cells from myelodysplastic syndrome patients: modulatory in-vitro effects of G-CSF and interferon-alpha. 2004 , 45, 1437-43	1
1131	Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. 2004 , 9, 171-7	24
1130	Differentiating juvenile myelomonocytic leukemia from chronic myeloid leukemia in childhood. 2004 , 26, 236-42	7
1129	The WHO classification of MDS does make a difference. 2004 , 103, 3265-70	117
1128	Myelodysplastic/myeloproliferative diseases. 2004 , 121, 13-43	10
1127	A basic classification and a comprehensive examination of pediatric myeloproliferative syndromes. 2005 , 27, 192-6	21
1126	Gene expression profiling in the myelodysplastic syndromes. 2005 , 10, 281-7	11
1125	A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. 2005 , 105, 3731-6	34
1124	Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. 2005 , 105, 443-52	78
1123	Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. 2005 , 105, 2664-70	332
1122	Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. 2005 , 106, 803-11	171
1121	Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. 2005 , 106, 2769-80	94
1120	Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. 2005 , 29, 41-6	34
1119	Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. 2005 , 29, 33-9	8
1118	Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. 2005 , 29, 215-24	119
1117	A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. 2005 , 29, 365-70	22

1116	Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. 2005 , 29, 325-9	38
1115	The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. 2005 , 29, 371-9	26
1114	A mighty supporter for WHO classification of myelodysplasia. 2005 , 29, 359-60	1
1113	Therapy-related myelodysplastic syndrome in childhood: a retrospective study of 36 patients in Japan. 2005 , 29, 625-32	19
1112	Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. 2005 , 29, 701-10	2
1111	Myelodysplastic syndromes in patients under 50 years old: a single institution experience. 2005 , 29, 749-54	19
1110	Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. 2005 , 29, 955-9	20
1109	Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. 2005 , 29, 987-93	18
1108	Increased CD133 expression in bone marrow of myelodysplastic syndromes. 2005 , 29, 995-1001	8
1107	Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases. 2005 , 29, 1435-41	9
1106	Modern diagnostics in acute leukemias. 2005 , 56, 223-34	50
1105	Management of patients with higher risk myelodysplastic syndromes. 2005 , 56, 179-92	19
1104	Hypocellular myelodysplastic syndromes: clinical and biological significance. 2005 , 22, 169-75	24
1103	Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients. 2005 , 22, 407-10	8
1102	Serial morphologic observation of bone marrow in aplastic anemia in children. 2005 , 81, 400-4	1
1101	Unrelated cord blood transplantation after myeloablative conditioning for adult patients with refractory anemia. 2005 , 81, 424-7	6
1100	Myelodysplastic syndrome. 2005 , 82, 412-6	1
1099	Refractory thrombocytopenia, an unusual myelodysplastic syndrome with an initial presentation mimicking idiopathic thrombocytopenic purpura. 2005 , 81, 142-7	9

1098	Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome. 2005 , 82, 66-71		3
1097	Identification and hematopoietic potential of CD45- clonal cells with very immature phenotype (CD45-CD34-CD38-Lin-) in patients with myelodysplastic syndromes. 2005 , 23, 619-30		19
1096	Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions. 2005 , 62, 75-85		3
1095	Del (9q) AML: clinical and cytological characteristics and prognostic implications. <i>British Journal of Haematology</i> , 2005 , 129, 210-20	4-5	42
1094	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. <i>British Journal of Haematology</i> , 2005 , 129, 791-4	4-5	19
1093	Evaluation of the monocyte counting by two automated haematology analysers compared with flow cytometry. 2005 , 27, 91-7		24
1092	Myelodysplastic syndrome associated with trisomy 2. 2005 , 27, 270-3		1
1091	Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. 2005 , 35, 455-61		16
1090	Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. 2005 , 19, 396-401		97
1089	Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. 2005 , 19, 776-83		94
1088	Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. 2005 , 19, 767-75		95
1087	Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. 2005 , 19, 1424-31		62
1086	AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. 2005 , 19, 1355-60		153
1085	Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. 2005 , 19, 1558-66		18
1084	Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. 2005 , 19, 1567-72		27
1083	A microRNA cluster as a target of genomic amplification in malignant lymphoma. 2005 , 19, 2013-6		177
1082	Risk factors of myelodysplastic syndromes: a case-control study. 2005 , 19, 1912-8		100
1081	Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). 2005 , 19, 2223-31		131

1080	Deletion of the inositide-specific phospholipase c beta1 gene is a rare event in myelodysplastic syndrome and thus of limited value to predict leukemic progression. 2005 , 19, 2011-3	4
1079	Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. 2005 , 24, 2441-8	63
1078	Long-term erythropoietin therapy improves response in myelodysplastic syndrome. 2005 , 9, 362-6	2
1077	Immunophenotyping of Myelodysplasia. 2005 , 5, 133-148	4
1076	Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases. 2005 , 157, 118-26	28
1075	Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases. 2005 , 160, 97-119	16
1074	A der(14)t(1;14)(q12;p11) in chronic myelomonocytic leukemia. 2005 , 160, 89-93	12
1073	Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes. 2005 , 33, 1357-62	16
1072	A method for rapid mouse siderocyte enrichment. 2005 , 33, 1493-9	4
1071	Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS). 2005 , 32, S11-5	54
1070	Introduction. 2005 , 32, 1-2	
1069	Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). 2005 , 32, S31-5	29
1068	A comparative review of classification systems in myelodysplastic syndromes (MDS). 2005 , 32, S3-10	48
1067	An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase. 2005 , 75, 73-7	3
1066	Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes. 2005 , 75, 193-8	2
1065	Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. 2005 , 43, 350-66	49
1064	Ionizing radiation and leukaemia: more questions than answers. <i>Hematological Oncology</i> , 2005 , 23, 119-263	18
1063	Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine. <i>American Journal of Hematology</i> , 2005 , 79, 216-9	7.1 9

1062	Hematologic disorders in 13 patients with acquired trisomy 21 and 13 individuals with Down syndrome. 1990 , 7, 247-50	5
1061	Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. 2005 , 54, 953-70	30
1060	Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. 2005 , 84, 298-303	9
1059	Clinical experience with decitabine in North American patients with myelodysplastic syndrome. 2005 , 84 Suppl 1, 18-24	7
1058	The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasia. 2005 , 84 Suppl 1, 67-79	5
1057	Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. 2005 , 84, 389-94	23
1056	Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). 2005 , 84, 429-33	48
1055	Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. 2005 , 84, 569-71	61
1054	Ocular complications in myelodysplastic syndromes as preleukemic disorders. 2005 , 49, 377-83	14
1053	Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders. 2005 , 44, 240-4	13
1052	Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS). 2005 , 28, 654-660	3
1051	Use of Camptothecins in the Treatment of Leukemia and Related Disorders. 2005 , 421-450	1
1050	Cytogenetic abnormalities in myelodysplastic syndromes. 2005 , 95-128	1
1049	Hematopoietic cell transplantation for myelodysplastic syndromes. 2005 , 243-262	
1048	The assessment of proliferating cell nuclear antigen immunostaining in myelodysplastic syndromes and its prognostic significance. 2005 , 49, 27-32	7
1047	Accumulation of an intron-retained mRNA for granulocyte macrophage-colony stimulating factor receptor common beta chain in neutrophils of myelodysplastic syndromes. 2005 , 77, 811-9	4
1046	Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update. 2005 , 46, 651-63	23
1045	Advances in myelodysplastic syndrome: nursing implications of azacitidine. 2005 , 9, 417-23	2

1044	Efficacy of lenalidomide in myelodysplastic syndromes. 2005 , 352, 549-57	712
1043	Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia. 2005 , 11, 1821-6	20
1042	Low Blast Count Myeloid Disorders With Auer Rods. 2005 , 124, 191-198	9
1041	Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. 2005 , 23, 7594-603	678
1040	Four-Color Flow Cytometry Shows Strong Concordance With Bone Marrow Morphology and Cytogenetics in the Evaluation for Myelodysplasia. 2005 , 124, 170-181	96
1039	Camptothecins in Cancer Therapy. 2005 ,	4
1038	Megakaryocytopoiesis and apoptosis in patients with myelodysplastic syndromes. 2005 , 46, 387-91	11
1037	The role of rHuEpo in low-risk myelodysplastic syndrome patients. 2005 , 46, 823-31	2
1036	Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. 2005 , 165, 2651-8	81
1035	FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. 2005 , 10, 176-82	333
1034	Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. 2005 , 11, 3604-8	322
1033	Impaired interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. 2005 , 77, 257-66	39
1032	Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. 2005 , 113, 146-9	12
1031	Recognition and Classification of Dysmyelopoiesis in the Dog: A Review. 2005 , 19, 147-154	21
1030	Management of anemia associated with myelodysplastic syndrome. 2005 , 42, S10-3	23
1029	Decitabine in myelodysplastic syndromes. 2005 , 42, S23-31	22
1028	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. 2005 , 46, 1345-51	36
1027	Clinical implications of blast immunophenotypes in myelodysplastic syndromes. 2005 , 46, 1269-74	19

1026	Myelodysplastic syndrome. 2005 , 56, 1-16	96
1025	Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. 2005 , 11, 65-73	96
1024	Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. 2005 , 11, 619-26	12
1023	[Iron overload in myelodysplastic syndromes. Role of iron chelators]. 2005 , 124, 654-5	
1022	Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. 2005 , 80, 681-98	39
1021	The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. 2005 , 106, 1207-9	399
1020	5-azacytidine and decitabine monotherapies of myelodysplastic disorders. 2005 , 39, 1700-9	25
1019	Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. 2006 , 355, 1456-65	1029
1018	The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. 2006 , 47, 599-602	27
1017	Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. 2006 , 47, 207-22	123
1016	Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. 2006 , 30, 105-12	11
1015	Concurrent development of Crohn disease and myelodysplastic syndrome in a child: case report and literature review. 2006 , 23, 477-83	1
1014	Clinical, hematological and cytogenetical data of 11 patients with myelodysplastic features and idiopathic thrombocytosis. 2006 , 47, 921-3	
1013	Prognostic significance of monocytosis in patients with myeloproliferative disorders. 2006 , 47, 417-23	17
1012	Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. 2006 , 47, 451-60	35
1011	Myelodysplastic/Myeloproliferative Disorder Overlap Syndrome: How Should it be Approached?. 2006 , 1, 95-100	1
1010	Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. 2006 , 19, 519-33	18
1009	Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined. 2006 , 19, 571-93	36

1008	Immunomodulation in myelodysplastic syndromes. 2006 , 19, 757-67	4
1007	Sphingolipid players in the leukemia arena. 2006 , 1758, 2121-32	11
1006	Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. 2006 , 12, 749-57	24
1005	The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. 2006 , 12, 876-84	215
1004	Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications. 2006 , 235, 177-90	17
1003	[Recent advances in the treatment of myelodysplastic syndromes]. 2006 , 27, 600-9	1
1002	The hematologic response to anti-apoptotic cytokine therapy: results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome. 2006 , 21, 40-5	2
1001	Erythrocyte and leucocyte cytochemistry. 2006 , 311-333	6
1000	Autoimmune Hemolytic Anemia in Myelodysplastic Syndrome. 2006 , 41, 317	1
999	Diagnosis and classification. 21-47	5
998	Bone Marrow Failure. 2006 ,	
997	Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. 2006 , 108, 2632-41	71
996	Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. 2006 , 108, 419-25	1125
995	Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. 2006 , 108, 337-45	165
994	Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. 2006 , 108, 1037-44	125
993	Myelodysplastic syndromes. 43-57	1
992	Diagnostic des syndromes my ^o lodysplasiques. 2006 , 1, 1-3	
991	Syndromes my ^o lodysplasiques et leuc ^o mies secondaires. 2006 , 1, 1-14	

990	Fatores prognósticos nas síndromes mielodisplásicas. 2006 , 28, 198		1
989	Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. <i>British Journal of Haematology</i> , 2006 , 132, 162-7	4.5	24
988	High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. <i>British Journal of Haematology</i> , 2006 , 133, 513-9	4.5	83
987	Platelet mass has prognostic value in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2006 , 135, 198-200	4.5	20
986	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2006 , 135, 317-23	4.5	29
985	Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. 2006 , 97, 133-8		34
984	Systematic review: managing anaemia in Crohn's disease. 2006 , 24, 1507-23		216
983	Evaluation of neoplastic human mast cells by tryptase-immunoelectron microscopy. 2006 , 48, 247-57		7
982	Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. 2006 , 20, 463-70		88
981	Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. 2006 , 30, 9-16		26
980	Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. 2006 , 30, 178-82		12
979	Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. 2006 , 30, 247-53		26
978	Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. 2006 , 30, 769-75		23
977	Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. 2006 , 30, 971-7		22
976	Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen. 2006 , 30, 935-42		7
975	Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. 2006 , 30, 957-63		19
974	Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. 2006 , 30, 1227-33		20
973	Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells. 2006 , 30, 1177-86		14

972	Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. 2006 , 30, 1235-9	24
971	The role of flow cytometric immunophenotyping in myelodysplastic syndromes. 2006 , 1089, 383-94	10
970	Successful reduced-intensity hematopoietic stem cell transplantation in myelodysplastic syndrome with severe coronary artery disease. 2006 , 83, 156-8	1
969	Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes. 2006 , 23, 37-49	12
968	Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. 2006 , 23, 385-91	31
967	Alterations of CD43 expression in transfusion-dependent myelodysplastic syndromes. 2006 , 85, 281-4	2
966	Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. 2006 , 85, 502-13	31
965	A case-control study of myelodysplastic syndromes in Belgrade (Serbia Montenegro). 2006 , 85, 514-9	25
964	Causes of incidental neutropenia in adulthood. 2006 , 85, 705-9	26
963	Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. 2007 , 86, 133-7	28
962	Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification. 2006 , 1, 9-15	
961	Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?. 2006 , 1, 16-9	2
960	Farnesyltransferase inhibitors in myelodysplastic syndrome. 2006 , 1, 20-4	2
959	New agents in myelodysplastic syndromes. 2006 , 1, 25-33	
958	Arsenic trioxide as a treatment for myelodysplastic syndrome. 2006 , 1, 34-8	3
957	Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. 2006 , 76, 23-32	155
956	Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients. 2006 , 76, 210-6	43
955	Frequencies and characterization of cytogenetically unrelated clones in various hematologic malignancies: seven years of experiences in a single institution. 2006 , 164, 128-32	15

954	Myelodysplastic syndromes with isolated deletion of the long arm of the chromosome X as a sole cytogenetic change. 2006 , 167, 47-50		4
953	Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. 2006 , 165, 51-63		25
952	Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia. 2006 , 167, 155-60		9
951	Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes. 2006 , 56, 191-9		4
950	Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. 2006 , 106, 1099-109		89
949	Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. 2006 , 106, 1794-803		1228
948	Treatment of acute myelogenous leukemia with outpatient azacitidine. 2006 , 107, 1839-43		67
947	Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. 2006 , 107, 2807-16		30
946	A case of myelodysplastic syndrome with erythroid hypoplasia associated with a familial translocation t(3;14)(p21.1;q24.1). <i>American Journal of Hematology</i> , 2006 , 81, 883-7	7.1	6
945	Fluorescence in situ hybridization reveals closely correlated results in cytological and histological specimens of hematological neoplasias compared to conventional cytogenetics. 2006 , 73, 271-9		4
944	Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. 2006 , 2006, 199-204		46
943	Biological Basis of Novel Therapies for Myelodysplastic Syndrome. 2006 , 2, 199-209		
942	Myelodysplastic syndromes in patients younger than age 50. 2006 , 24, 5358-65		82
941	Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. 2006 , 12, 3099-108		21
940	Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS. 2006 , 6, 553-65		7
939	Evaluation of dysmyelopoiesis in cats: 34 cases (1996-2005). 2006 , 228, 893-7		20
938	Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. 2007 , 104, 1307-12		63
937	Going from genes to proteins in myelodysplastic syndromes. 2007 , 104, 1109-10		1

936	Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. 2007 , 127, 197-205	73
935	The evolving role of lenalidomide in the treatment of hematologic malignancies. 2007 , 8, 497-509	44
934	Multiparametric Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes and Related Disorders. 2007 , 38, 305-313	4
933	Circulating adiponectin and leptin in relation to myelodysplastic syndrome: a case-control study. 2007 , 73, 26-32	30
932	Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. 2007 , 48, 1150-60	51
931	A pilot study of bendamustine in elderly patients with high-risk MDS and AML. 2007 , 48, 1161-6	11
930	Modern Hematology. 2007 ,	15
929	Analysis of FLT3 gene mutations in de novo myelodysplastic syndromes. FLT3 internal tandem duplication detected in a case of refractory anemia. 2007 , 48, 2437-40	2
928	BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. 2007 , 67, 11657-67	49
927	Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival. 2007 , 117, 221-5	3
926	Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches. 2007 , 7, 541-58	24
925	The reduced GM-CSF priming of ROS production in granulocytes from patients with myelodysplasia is associated with an impaired lipid raft formation. 2007 , 81, 449-57	21
924	Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. 2007 , 25, 3503-10	810
923	[Guideline for the care of hematologic diseases based on EBM]. 2007 , 96, 475-82	
922	Chronic myelomonocytic leukemia in the light of the WHO proposals. 2007 , 92, 974-7	62
921	Myeloproliferative/Myelodysplastic Diseases. 461-471	1
920	A dog with myelodysplastic syndrome: chronic myelomonocytic leukemia. 2007 , 69, 665-8	8
919	Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. 2007 , 110, 1379-87	125

918	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. 2007 , 110, 4385-95	585
917	Evolving classifications of the myelodysplastic syndromes. 2007 , 14, 98-105	13
916	Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1). 2007 , 29, 839-40	3
915	Transformation of childhood MDS-refractory anemia to acute lymphoblastic leukemia. 2007 , 29, 725-7	11
914	A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. 2007 , 92, 744-52	122
913	New insights into the pathobiology and treatment of chronic myelogenous leukemia. 2007 , 11, 68-78	20
912	Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. 2007 , 13, 345-54	40
911	Clinical features and prognosis of patients with myelodysplastic syndromes. 2007 , 33, S15-S18	4
910	A comprehensive approach to the diagnosis of MDS after triage by morphology towards cytogenetics and other techniques. 2007 , 33, S31-S41	1
909	Bone marrow morphology and classification systems in myelodysplastic syndromes. 2007 , 33, S2-S5	2
908	Cytogenetic subtypes of MDS [Molecular background, prognostic relevance and therapeutic consequences. 2007 , 33, S25-S30	
907	The pathogenesis of myelodysplastic syndromes (MDS). 2007 , 33, S53-S58	7
906	[Myelodysplastic syndromes in adults]. 2007 , 36, 481-91	2
905	Late hematological effects in the atomic bomb survivors. 2007 , 1299, 67-72	3
904	Autologous stem cell transplantation in myelodysplastic syndromes. 2007 , 44, 274-7	9
903	The changing face of chronic lymphocytic leukemia. 2007 , 48, 2283-4	2
902	FAB and beyond. 2007 , 48, 2282-3	1
901	Wilms' tumor gene (WT1) is predominantly expressed in clonal hematopoietic cells in myelodysplastic syndromes. 2007 , 48, 601-4	10

890	Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. 2007 , 1, 353-356	6
899	Myelodysplastic Syndromes: Impact of Recently Analyzed Variables for Modifying Current Classification Methods. 2007 , 1, 172-182	2
898	Risk assessment in haematopoietic stem cell transplantation: disease and disease stage. 2007 , 20, 125-54	22
897	Cancer in Fanconi Anemia and Fanconi Anemia Genes in Cancer. 2007 , 59-78	2
896	Myelodysplastic Syndromes. 2007 , 1-4	
895	. 2007 ,	36
894	Chemiluminescent determination of leukocyte alkaline phosphatase: an advantageous alternative to the cytochemical assay. 2007 , 21, 91-6	4
893	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. 2007 , 109, 265-73	94
892	A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. 2007 , 109, 1125-32	27
891	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. 2007 , 109, 1133-7	158
890	Myelodysplastic syndromes: incidence and survival in the United States. 2007 , 109, 1536-42	415
889	The incidence and impact of thrombocytopenia in myelodysplastic syndromes. 2007 , 109, 1705-14	179
888	Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. 2007 , 110, 345-52	92
887	Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. 2007 , 21, 49-59	14
886	Allogeneic transplantation for myelodysplastic syndrome (MDS). 2007 , 21, 61-71	14
885	Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. 2007 , 31, 147-55	44
884	Aberrant methylation in pediatric myelodysplastic syndrome. 2007 , 31, 175-81	34
883	Pro-inflammatory cytokinemia is frequently found in Down syndrome patients with hematological disorders. 2007 , 31, 1199-203	26

882	Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. 2007 , 31, 1373-82	22
881	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. 2007 , 31, 727-36	393
880	Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome. 2007 , 31, 1097-1105	6
879	Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. 2007 , 31, 1461-8	69
878	Increased apoptosis of circulating T cells in myelodysplastic syndromes. 2007 , 31, 1641-8	14
877	Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. 2007 , 31, 1609-16	40
876	Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. 2007 , 49, 17-22	61
875	Myelodysplastic syndromes: the complexity of stem-cell diseases. 2007 , 7, 118-29	271
874	Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. 2007 , 40, 759-64	19
873	Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. 2007 , 21, 480-8	17
872	A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. 2007 , 21, 668-77	51
871	Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. 2007 , 21, 992-7	41
870	Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. 2007 , 21, 1436-41	114
869	A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). 2007 , 21, 1945-51	28
868	Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia. 2007 , 21, 2390-3	24
867	The haematocrit and platelet target in polycythemia vera. <i>British Journal of Haematology</i> , 2007 , 136, 249-59	4.5 143
866	Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. <i>British Journal of Haematology</i> , 2007 , 137, 206-15	4.5 52
865	Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2007 , 137, 125-32	4.5 63

864	Platelet morphology, platelet mass, platelet count and prognosis in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2007 , 138, 399-400	4-5	10
863	Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. <i>British Journal of Haematology</i> , 2007 , 139, 578-89	4-5	130
862	Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. 2007 , 37, 435-53		579
861	Evolving trends in the treatment of low-risk myelodysplastic syndromes: immunomodulation and beyond--9th European Hematology Association Congress Geneva, Switzerland, 10-13 June 2004. 2007 , 17, 151-60		3
860	Sweet's syndrome associated with skin methicillin-resistant <i>Staphylococcus epidermidis</i> infection. 2007 , 34, 258-61		4
859	Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer. 2007 , 27, 434-46		4
858	Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?. 2007 , 176, 1-21		20
857	Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and trivalent chromosomes, resulting in the loss of critical 5q regions. 2007 , 175, 125-31		9
856	Enhanced growth of myelodysplastic colonies in hypoxic conditions. 2007 , 35, 21-31		25
855	High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. 2007 , 35, 240-51		28
854	Recent advances in myelodysplastic syndromes. 2007 , 35, 137-43		40
853	DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. 2007 , 35, 712-23		30
852	Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. 2007 , 35, 1739-46		97
851	Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. 2007 , 78, 457-67		20
850	Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes. 2008 , 80, 107-14		4
849	Immunomodulatory therapy for myelodysplastic syndromes. 2007 , 86, 301-5		9
848	Evolving new treatment for myelodysplastic syndromes. 2007 , 86, 297-300		0
847	A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response. 2007 , 86, 150-7		18

846	High incidence of morphological myelodysplasia and apoptotic bone marrow cells in Behçet's disease. 2007 , 27, 145-51	8
845	Current treatment options: impact of cytogenetics on the course of myelodysplasia. 2007 , 8, 117-28	24
844	Iron overload in patients with myelodysplastic syndromes. 2007 , 2, 13-21	6
843	The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS. 2007 , 24, 419-24	4
842	Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?. 2008 , 19, 371-8	14
841	Concurrent inflammatory bowel disease and myelodysplastic syndrome: report of nine new cases and a review of the literature. 2008 , 53, 1929-32	10
840	Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. 2008 , 87, 537-44	32
839	Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. 2008 , 87, 691-9	70
838	Lenalidomide in myelodysplastic syndromes: where do we go from here?. 2008 , 3, 5-9	
837	Prognosis in myelodysplastic syndromes: are the new classifications useful?. 2008 , 3, 19-22	
836	Diagnosis and management of chronic myelomonocytic leukemia. 2008 , 3, 31-6	4
835	Myelodysplastic syndrome: an update on diagnosis and therapy. 2008 , 10, 372-8	5
834	Hemogram and bone marrow morphology in children with chronic aplastic anemia and myelodysplastic syndrome. 2008 , 4, 36-40	1
833	Clonality investigation of morphologically dysplastic hematopoietic cells in myelodysplastic syndrome marrows. 2008 , 87, 176-183	2
832	Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. 2008 , 88, 24-29	87
831	Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children. 2008 , 88, 524-529	6
830	[Individualized management and therapy of myelodysplastic syndromes]. 2008 , 120, 523-37	5
829	Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. 2008 , 112, 1089-95	57

828	Diagnostic flow cytometry for low-grade myelodysplastic syndromes. <i>Hematological Oncology</i> , 2008 , 26, 193-8	1.3	23
827	Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders. <i>American Journal of Hematology</i> , 2008 , 83, 531-9	7.1	10
826	Prognostic relevance of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2008 , 83, 761-2	7.1	3
825	Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. 2008 , 32, 33-7		27
824	Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. 2008 , 32, 251-4		11
823	Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. 2008 , 32, 215-24		74
822	Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. 2008 , 32, 514-6		26
821	Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. 2008 , 32, 407-11		14
820	Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). 2008 , 32, 587-91		104
819	Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. 2008 , 32, 1043-8		17
818	Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. 2008 , 32, 1407-16		78
817	Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. 2008 , 32, 1333-7		12
816	Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. 2008 , 32, 1715-23		18
815	Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members. 2008 , 32, 1820-3		4
814	Supportive care, growth factors, and new therapies in myelodysplastic syndromes. 2008 , 22, 75-91		18
813	The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. 2008 , 22, 1308-19		143
812	Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. 2008 , 22, 1335-42		103
811	Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. 2008 , 22, 1874-81		17

810	Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. 2008 , 21, 1394-402		38
809	Abstracts of the XXIst International Symposium on Technological Innovations in Laboratory Hematology. April 28-May 1, 2008. Sydney, Australia. 2008 , 30 Suppl 1, 1-147		3
808	Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. 2008 , 22, 313-22		78
807	A prognostic score for patients with lower risk myelodysplastic syndrome. 2008 , 22, 538-43		244
806	Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. 2008 , 22, 544-50		43
805	Bone marrow trephine morphology and immunohistochemical findings in chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2008 , 141, 771-81	4.5	20
804	Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. <i>British Journal of Haematology</i> , 2008 , 142, 57-64	4.5	79
803	Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2008 , 142, 379-93	4.5	66
802	Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. 2008 , 38, 143-9		45
801	Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression. 2008 , 38, 447-55		14
800	Revealing the pathogenesis of the 5q- syndrome. 2008 , 38, 539-40		
799	Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. 2008 , 38, 945-52		40
798	A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. <i>British Journal of Haematology</i> , 2008 , 65, 307-311	4.5	
797	Clonal chromosomal abnormalities in Fanconi's anaemia: what do they really mean?. <i>British Journal of Haematology</i> , 1993 , 85, 627-30	4.5	29
796	Myelodysplastic syndrome in a kindred with ins(16) (p11.2). 1988 , 33, 418-23		8
795	Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. 2008 , 76, 1417-25		27
794	Chromosome instability is associated with hypodiploid clones in myelodysplastic syndromes. 1984 , 101, 19-30		28
793	Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?. 2008 , 151, 240-5		24

792	World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. 2008 , 45, 3-7	13
791	Targeted Cancer Therapy. 2008 ,	6
790	Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. 2008 , 44, 1744-53	37
789	Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. 2008 , 14, 1341-7	49
788	Identification and functional characterization of novel telomerase variant alleles in Japanese patients with bone-marrow failure syndromes. 2008 , 40, 185-191	21
787	Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. 2008 , 45, 14-22	39
786	Myelodysplastic syndrome in children and adolescents. 2008 , 45, 60-70	43
785	Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality. 2008 , 2, 28-33	3
784	Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy. 2008 , 2, 205-211	58
783	What Is WHO Myelodysplastic Syndromes Classification. 2008 , 2, 20-27	1
782	Proposals for a Grading System for Diagnostic Accuracy of Myelodysplastic Syndromes. 2008 , 2, 102-106	6
781	The Epidemiology of Myelodysplastic Syndromes. 2008 , 2, 34-38	6
780	Myelodysplastic syndromes. 2008 , 111, 4841-51	292
779	Treatment strategies in myelodysplastic syndromes. 2008 , 26, 208-16	9
778	Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. 2008 , 100, 1542-51	209
777	Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. 2008 , 19, 970-6	30
776	Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany. 2008 , 31, 477-84	2
775	Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. 2008 , 105, 2865-70	110

774	Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. 2008 , 14, 509-14	19
773	Clinician Manual on Myelodysplastic Syndromes. 2008 ,	
772	Solving the mystery of myelodysplasia. 2008 , 5, e40	3
771	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. 2008 , 93, 1001-8	27
770	Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. 2008 , 49, 1292-6	8
769	Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?. 2008 , 49, 1225-7	2
768	[Myelodysplastic syndromes: clinically relevant aspects in diagnosis, prognosis and prediction]. 2008 , 133, 2086-90	1
767	Reduced activation of protein kinase B, Rac, and F-actin polymerization contributes to an impairment of stromal cell derived factor-1 induced migration of CD34+ cells from patients with myelodysplasia. 2008 , 111, 359-68	38
766	Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. 2008 , 111, 86-93	351
765	Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. 2008 , 111, 2527-37	290
764	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. 2008 , 111, 574-82	243
763	MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. 2008 , 111, 1855-61	54
762	Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. 2008 , 112, 2681-6	97
761	The role of flow cytometry in myelodysplastic syndromes. 2008 , 6, 935-41	10
760	Behçet disease associated with myelodysplastic syndrome. 2008 , 14, 169-74	33
759	Nonarteritic anterior ischemic optic neuropathy associated with chronic anemia: a case series of myelodysplastic syndrome patients. 2008 , 133	1
758	Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. 2008 , 93, 1402-6	19
757	Myeloproliferative syndrome of monosomy 7: a brief report. 2008 , 31, 36-38	

756	High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site. 2008 , 49, 549-55	20
755	Differential gene expression of bone marrow CD34+ cells in early and advanced myelodysplastic syndrome. 2009 , 56, 335-42	5
754	Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of myelodysplastic syndrome. 2009 , 42, 1110-2	18
753	Defective ribosome biogenesis in myelodysplastic syndromes. 2009 , 94, 1336-8	2
752	Management of Multiple Myeloma and Myelodysplastic Syndrome: Focus on Lenalidomide. 2009 , 1, CMT.S2295	
751	G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. 2009 , 94, 1449-52	31
750	Myelodysplastic syndromes. 2009 , 132, 290-305	44
749	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 2009 , 106, 16811-6	88
748	Acute Myeloid Leukaemia, Mixed Phenotype Acute Leukaemia, The Myelodysplastic Syndromes and Histiocytic Neoplasms. 166-238	
747	Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. 2009 , 169, 1492-9	55
746	Bone Marrow. 2009 , 1536-1593	
745	The myelodysplastic syndromes. 2009 , 71-79	
744	Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow. 2009 , 47, 419-26	1
743	The changing classification of myelodysplastic syndromes: what's in a name?. 2009 , 645-55	14
742	Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia. 2009 , 94, 1075-84	6
741	Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia. 2009 , 94, 1338-40	8
740	A study of the reproducibility of the diagnostic criteria for acute leukaemia. 1983 , 31, 257-66	21
739	The blasted immature cells in the bone marrow. 1983 , 30, 492-3	2

738	Refractory anaemia with excess of blasts terminating as Ph1 negative chronic myeloid leukaemia. 1984 , 32, 493-5	5
737	Acute leukaemia in a defined geographic area--incidence, clinical history and prognosis. 1984 , 33, 160-70	8
736	Myeloperoxidase-deficient polymorphonuclear leucocytes. (V): Relation to FAB-classification and neutrophil alkaline phosphatase activity in primary myelodysplastic syndromes. 1985 , 35, 197-200	18
735	Leukaemia cell mobility in childhood acute myeloid leukaemia based on the FAB classification. 1985 , 35, 481-6	1
734	Platelet peroxidase of circulating thrombocytes in acquired refractory anaemias. 1986 , 36, 194-7	
733	The myelodysplastic syndromes. 2009 , 36, 11-20	16
732	Bone marrow histology in myelodysplastic syndromes. 1986 , 45, 21-37	21
731	Ferrokinetic abnormalities and red cell life span in myelodysplastic syndromes: a review. 1986 , 45, 48-52	
730	Sideroblasts in myelodysplasia: their nature and clinical significance. 1986 , 45, 53-5	9
729	Red cell enzymes in myelodysplastic syndromes: a review. 1986 , 45, 56-9	4
728	Cytogenetics of the myelodysplastic syndromes. 1986 , 45, 74-7	14
727	Translocation (2;11) (p21;q23) in acute non-lymphocytic leukaemia: a non-random association. 1986 , 45, 91-7	10
726	Natural course of myelodysplastic syndromes--Helsinki experience. 1986 , 45, 102-6	11
725	Prognostic factors in the myelodysplastic syndromes: a review. 1986 , 45, 107-13	24
724	Preleukaemia: a long-term prospective study of 326 patients. 1986 , 45, 114-20	27
723	Primary myelodysplastic syndrome: treatment of 6 patients with 13-cis retinoic acid. 1986 , 45, 128-32	6
722	Preleukaemic states in children. 1986 , 45, 133-9	21
721	Type III aminoterminal propeptide of procollagen in some haematological malignancies. 1986 , 36, 288-94	11

720	Cytogenetic analysis in 941 consecutive patients with haematologic disorders. 1986 , 37, 29-40	14
719	Impaired alpha-interferon production and natural killer activity in blood mononuclear cells in myelodysplastic syndromes. 1986 , 37, 111-7	12
718	Immunocytochemical detection of normal and abnormal megakaryocytes using monoclonal antibody to glycoprotein IIb-IIIa (TP80): the quantitative assay in normal and in leukaemic patients. 1986 , 36, 415-23	14
717	Myeloperoxidase-deficient polymorphonuclear leucocytes (VI): Relation to cytogenetic abnormalities in primary myelodysplastic syndromes. 1986 , 36, 3-7	6
716	Correlation between bone marrow karyotype and the occurrence of erythroblast micronuclei and nuclear budding in patients with myelodysplastic syndromes. 1987 , 39, 237-40	5
715	Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts. 1987 , 39, 278-81	9
714	Specificity of haematological indicators for '5q- syndrome' in patients with myelodysplastic syndromes. 1987 , 39, 326-30	12
713	Danazol in the treatment of myelodysplastic syndromes. 1987 , 39, 346-8	21
712	Cytogenetic studies in 69 patients with myelodysplastic syndromes (MDS). 1987 , 38, 166-72	37
711	Refractory anaemia according to the FAB classification: a report on 69 cases. 1988 , 40, 318-25	10
710	Bone marrow karyotype and prognosis in primary myelodysplastic syndromes. 1988 , 41, 341-6	47
709	Application of megakaryocytic morphology in diagnosing 5q- syndrome. 1988 , 41, 434-7	22
708	Prognostic parameters in myelodysplastic syndromes: a multiple regression analysis. 1988 , 40, 158-62	12
707	Myelodysplastic syndromes: analysis of clinical and prognostic features in 96 patients. 1988 , 41, 115-22	22
706	Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors. 1989 , 42, 284-8	6
705	A myelokathexis-like variant of myelodysplasia. 1989 , 42, 99-102	12
704	Effects of recombinant G-CSF and GM-CSF on in vitro differentiation of the blast cells of RAEB and RAEB-T. 1989 , 42, 348-53	5
703	Colony formation by megakaryocyte progenitors in myelodysplastic syndromes. 1989 , 42, 389-95	12

702	Chronic myelomonocytic leukemia with chromosomal changes involving 1p36 and hepatocellular carcinoma in a case of Fanconi's anemia. 1989 , 42, 492-5	8
701	Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. 1990 , 44, 30-2	29
700	Systemic lupus erythematosus associated with refractory anemia with excess of blasts. 1990 , 44, 79-80	
699	Comparative study of immunocytochemical staining versus Giemsa stain for detecting dysmegakaryopoiesis in myelodysplastic syndromes (MDS). 1990 , 44, 89-94	5
698	Clinical, biochemical and cytokinetic parameters for distinguishing smouldering and rapidly proliferating variants of acute leukaemia. 1990 , 45, 19-25	11
697	Sweet's syndrome in association with myelodysplastic syndrome. 1990 , 45, 184-6	6
696	Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b. 1991 , 46, 11-6	20
695	Chronic granulocytic leukemia: reassessment of morphologic and cytogenetic characteristics in Ph1-positive and Ph1-negative cases. 1991 , 46, 77-84	1
694	Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). 1991 , 47, 17-27	100
693	Growth response to cytokines of circulating myeloid progenitors from myelodysplastic patients at diagnosis and more than 600 days after diagnosis. 1991 , 47, 65-70	3
692	Danazol: in vitro effects on human hemopoiesis and in vivo activity in hypoplastic and myelodysplastic disorders. 1991 , 47, 197-203	14
691	Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. 1991 , 47, 277-81	31
690	Treatment of myelodysplastic syndromes with human granulocytic-macrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside. 1992 , 49, 138-42	12
689	Myelofibrosis in primary myelodysplastic syndromes. 2009 , 48, 208-214	84
688	Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes. 1993 , 51, 56-8	20
687	Revisited indications for bone marrow examinations in HIV-infected patients. 1994 , 53, 168-74	10
686	Effects of recombinant human stem cell factor (rh-SCF) on colony formation and long-term bone marrow cultures (LTBMC) in patients with myelodysplastic syndromes. 1994 , 52, 53-60	13
685	Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients. 1994 , 53, 280-7	28

684	Lineage involvement and karyotype in a patient with myelodysplasia and blood basophilia. 1994 , 53, 288-92	6
683	Automated measurement of reticulated platelets in estimating thrombopoiesis. 1995 , 54, 163-71	39
682	Epstein-Barr virus infection is not frequent in bone marrow from patients with myelodysplastic syndromes. 1995 , 55, 199-201	1
681	Treatment of 34 patients with myelodysplastic syndromes with 13-CIS retinoic acid. 1995 , 55, 235-9	12
680	Refractory anemia with excess of blasts: a multivariate analysis of prognostic factors in 91 patients and a simplified scoring system for predicting survival. 1995 , 54, 241-4	6
679	Cytoplasmic abnormalities of erythroblasts as a marker for ringed sideroblasts in myelodysplastic syndromes. 1995 , 54, 276-8	1
678	Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. 1995 , 54, 39-45	12
677	Proliferation and differentiation of myelodysplastic CD34+ cells in serum-free medium: II. Response to combined colony-stimulating factors. 1995 , 54, 85-94	4
676	Use of a functional classification of anemia in myelodysplastic syndromes to identify subgroups of patients responsive to recombinant human-erythropoietin therapy. 1996 , 56, 106-8	1
675	Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry. 1996 , 56, 124-9	18
674	Production of tumor necrosis factor and granulocyte colony stimulating factor by bone marrow accessory cells in myelodysplastic patients. 1996 , 56, 148-52	6
673	Serum procollagen III peptide concentration in iron overload. 1996 , 57, 157-64	7
672	Bone marrow patterns in patients with aplastic anaemia and myelodysplastic syndrome: observations with magnetic resonance imaging. 1997 , 59, 155-61	11
671	Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload. 1997 , 59, 221-30	12
670	Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. 1998 , 61, 347-53	23
669	Incidence of nucleoli in erythroblasts in patients suffering from refractory anemia of myelodysplastic syndrome. 1999 , 63, 332-6	
668	Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. 1999 , 62, 90-4	23
667	A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender. 1999 , 62, 95-102	44

666	Refractory anemia with excess of blasts: increased survival when treated with cyclophosphamide, methotrexate and 6-mercaptopurine. 1999 , 62, 213-8		1
665	Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha. 1999 , 62, 336-40		
664	Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. 2009 , 83, 477-82		50
663	Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia. 2009 , 83, 550-8		4
662	Accelerated cellular senescence in myelodysplastic syndrome. 2009 , 37, 1310-7		14
661	Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS. 2009 , 193, 78-85		19
660	Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes. 2009 , 194, 119-24		24
659	A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2009 , 84, 560-4	7.1	36
658	Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele. <i>Hematological Oncology</i> , 2010 , 28, 98-103	1.3	5
657	Myelodysplastic syndromes and acute myeloid leukemia in cats infected with feline leukemia virus clone33 containing a unique long terminal repeat. 2009 , 124, 1133-41		23
656	Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). 2009 , 115, 84-93		6
655	The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. 2009 , 115, 4524-32		17
654	Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. <i>Cytometry Part B - Clinical Cytometry</i> , 2009 , 76, 27-36	3.4	56
653	Therapy related CMML: a case report and review of the literature. 2009 , 89, 699-703		13
652	Myelodysplastic syndrome: An update on diagnosis and therapy. 2009 , 4, 10-6		1
651	Analysis of WHO-based Prognostic Scoring System (WPSS) of myelodysplastic syndrome and its comparison with international prognostic scoring system (IPSS) in 100 Chinese patients. 2009 , 21, 50-55		2
650	Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS). 2009 , 2, 13-17		
649	Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes. 2009 , 88, 607-11		7

648 Avanc^es cytogⁿétiques dans les syndromes my^élodysplasiques. **2009**, 2009, 59-66

647 10 Myelodysplastic syndromes: update on classification. **2009**, 33, S6-S8

1

646 11 Real-time prognostic evaluation in MDS. **2009**, 33, S8-S9

645 Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?. **2009**, 52, 357-63

23

644 Treatment of children with refractory anemia: the Japanese Childhood MDS Study Group trial (MDS99). **2009**, 53, 1011-5

17

643 Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?. *British Journal of Haematology*, **2009**, 144, 809-17

4.5 29

642 Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. *British Journal of Haematology*, **2009**, 145, 788-800

4.5 460

641 NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes. *British Journal of Haematology*, **2009**, 146, 538-45

4.5 19

640 Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. *British Journal of Haematology*, **2009**, 146, 627-36

4.5 50

639 Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. *British Journal of Haematology*, **2010**, 149, 844-54

4.5 25

638 Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. **2009**, 39, 406-11

27

637 Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. **2009**, 39, 548-53

62

636 Myelodysplastic syndromes: biology and treatment. **2009**, 265, 307-28

44

635 RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. **2009**, 23, 1426-31

123

634 Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. **2009**, 23, 1605-13

77

633 Étiologie des syndromes my^élodysplasiques (SMD) et des syndromes my^élodysplasiques/syndromes my^éloprolif^ératifs (SMD/SMP). **2009**, 2009, 25-29

1

632 Classification des syndromes my^élodysplasiques. **2009**, 2009, 49-57

4

631 Neutrophil function and cytokine-specific signaling in chronic neutrophilic leukemia. **2009**, 31, 36-47

2

630	Promoter methylation of P15(INK4B) gene is possibly associated with parvovirus B19 infection in adult acute leukemias. 2009 , 31, 407-19	12
629	Do peripheral blasts count in myelodysplastic syndromes?. 2009 , 33, 209-11	4
628	Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. 2009 , 33, 391-4	3
627	Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes. 2009 , 33, 326-31	13
626	New recurrent deletions in the PPARgamma and TP53 genes are associated with childhood myelodysplastic syndrome. 2009 , 33, 19-27	10
625	John Auer and Auer rods; controversies revisited. 2009 , 33, 614-6	12
624	Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders. 2009 , 33, 617-23	6
623	Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. 2009 , 33, 1594-8	68
622	The significance of bone marrow cell morphology and its correlation with cytogenetic features in the diagnosis of MDS-RA patients. 2009 , 33, 1029-38	14
621	Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. 2009 , 33, 1189-93	16
620	Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes. 2009 , 33, 1183-8	8
619	Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania. 2009 , 33, 1556-61	10
618	Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia. 2009 , 33, e207-9	3
617	IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. 2009 , 15, 205-13	18
616	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. 2009 , 15, 137-72	59
615	Hematopoiesis-related microRNA expression in myelodysplastic syndromes. 2009 , 50, 1854-9	74
614	Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. 2009 , 113, 6403-10	309
613	Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. 2009 , 69, 2501-18	20

612	Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. 2009 , 48, 1222-6		28
611	The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders. 2009 , 50, 427-36		8
610	Update on genetic and molecular markers associated with myelodysplastic syndromes. 2009 , 50, 341-8		6
609	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. 2009 , 10, 223-32		1961
608	Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. <i>American Journal of Hematology</i> , 2009 , 84, 215-20	7.1	56
607	The myelodysplastic syndromes. 2009 , 23, 675-91		20
606	[Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004]. 2009 , 57, 151-8		19
605	Hematological malignancies: Incidence in Basse-Normandie, France, for 1997-2004. 2009 , 57, e17-e24		
604	Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms and Related Conditions. 239-299		
603	Treatment of MDS: something old, something new, something borrowed. 2009 , 656-63		4
602	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. 2009 , 113, 3947-52		133
601	How I treat patients with myelodysplastic syndromes. 2009 , 113, 6296-303		68
600	Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. 2009 , 114, 1063-72		125
599	Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). 2009 , 114, 2393-400		150
598	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). 2009 , 114, 3285-91		231
597	Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. 2009 , 114, 2575-80		10
596	The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. 2010 , 33, 523-37		30
595	Acute Myeloid Leukemia and Myelodysplastic Disorders. 2010 , 95-108		1

594	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. 2010 , 95, 1754-61	62
593	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. 2010 , 95, 892-9	16
592	Demethylating Agents in the Treatment of Cancer. 2010 , 3, 2022-2044	41
591	Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. 2010 , 89, 365-74	64
590	Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study. 2010 , 89, 535-44	16
589	Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. 2010 , 91, 97-103	15
588	Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes. 2010 , 91, 602-10	8
587	Cytogenetic Study of Myelodysplastic Syndrome. 2010 , 7, 46-50	
586	Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. 2010 , 32, 2444-56	20
585	Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. 2010 , 196, 159-66	20
584	Isochromosome 5p and related anomalies: a novel recurrent chromosome abnormality in myeloid disorders. 2010 , 200, 134-9	5
583	Adult B-cell acute lymphoblastic leukemia with two unrelated abnormal cytogenetic clones. 2010 , 201, 24-7	1
582	Epigenetic therapy in myelodysplastic syndromes. 2010 , 84, 463-73	32
581	Reasons for treating secondary AML as de novo AML. 2010 , 85, 217-26	40
580	Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. 2010 , 116, 1485-94	85
579	Cause of death in patients with lower-risk myelodysplastic syndrome. 2010 , 116, 2174-9	109
578	Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. 2010 , 116, 2372-81	42
577	Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. 2010 , 116, 4549-63	73

576	Nuclear inositide signaling in myelodysplastic syndromes. 2010 , 109, 1065-71		22
575	Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2010 , 78, 154-68	3-4	29
574	Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. <i>American Journal of Hematology</i> , 2010 , 85, 765-70	7.1	21
573	Outcome of patients with myelodysplastic syndromes in the Veterans Administration population. 2010 , 34, 59-62		12
572	Incorporating novel agents in the treatment of myelodysplastic syndromes. 2010 , 34, 6-17		9
571	Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. 2010 , 34, 487-91		12
570	Right and left shifts for age in MDS. 2010 , 34, 409-10		1
569	Adding FISH to karyotype in Myelodysplastic syndrome investigation diagnosis: are all questions answered?. 2010 , 34, 413-5		3
568	Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. 2010 , 34, 981-5		21
567	Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. 2010 , 34, 974-80		21
566	Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. 2010 , 34, 986-90		23
565	Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des My ^l lodysplasies). 2010 , 34, 864-70		150
564	Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients. 2010 , 34, 939-41		4
563	From FAB to 2008 WHO classification: the wide heterogeneity of refractory anemia subtype among different countries. 2010 , 34, 967-8		1
562	Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome. 2010 , 34, 991-4		6
561	Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. 2010 , 34, 1224-31		38
560	Improvement of the WHO classification-based prognostic scoring system (WPSS) by including age for Korean patients with the myelodysplastic syndrome. 2010 , 34, 1589-95		
559	Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. 2010 , 34, 1410-6		43

558	The lower risk MDS patient at risk of rapid progression. 2010 , 34, 1551-5		42
557	Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes. 2010 , 3, 23		27
556	Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. 2010 , 50, 190-9		33
555	Current therapeutic approaches for patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2010 , 150, 131-43	4-5	23
554	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2010 , 151, 365-75	4-5	175
553	Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q). 2010 , 24, 1875-84		11
552	Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. 2010 , 24, 756-64		197
551	Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. 2010 , 45, 450-7		29
550	Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors - International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues. 2010 , 1, 171-82		18
549	Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. 307-328		
548	Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome. 2010 , 2, e2010019		1
547	CD71 (transferrin receptor): an effective marker for erythroid precursors in bone marrow biopsy specimens. 2010 , 134, 429-35		74
546	Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. 2010 , 21, 120-5		49
545	Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. 2010 , 2010, 164045		36
544	Leukocyte alkaline phosphatase score correlation with bone marrow blast percentage in myelodysplastic syndrome. 2010 , 124, 179-81		
543	Immune dysregulation in myelodysplastic syndrome. 2010 , 2, e1		14
542	RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. 2010 , 16, 2246-56		103
541	Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. 2010 , 51, 783-8		15

540	An update on the treatment of myelodysplastic syndromes. 2010 , 14, E29-44	10
539	HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. 2010 , 45, 1333-9	24
538	Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. 2010 , 21, 114-9	91
537	Incidence and survival of lymphohematopoietic neoplasms according to the World Health Organization classification: a population-based study from the Victorian Cancer Registry in Australia. 2010 , 51, 456-68	11
536	Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond. 2010 , 10, 605-14	10
535	Benzene and human health: A historical review and appraisal of associations with various diseases. 2010 , 40 Suppl 2, 1-46	67
534	Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization. 2010 , 203, 193-202	5
533	Current and future management options for myelodysplastic syndromes. 2010 , 70, 1381-94	9
532	Acute Myeloid Leukemia With Myelodysplasia-Related Changes: A New Definition. 2010 , 3, 1153-64	11
531	Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. 2010 , 51, 2250-7	12
530	Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms. 2010 , 123-144	
529	Myelodysplastic syndromes: what a primary care physician needs to know. 2010 , 56, 468-78	1
528	The evolving clinical scenario of myelodysplastic syndrome: the need for a complete and up to date upfront diagnostic assessment. 2010 , 21, 490-5	6
527	Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. 2010 , 16, 1-11	8
526	Myelodysplastic syndromes: from neglect to prominence. 2010 , 16, S28-9	
525	Myelodysplastic syndromes classification and risk stratification. 2010 , 24, 443-57	48
524	Myelodysplastic syndromes. 2010 , 61, 345-58	41
523	GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies. 2010 , 29, 111	10

522	Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). 2010 , 116, 3735-42	127
521	Cytogenetic risk stratification in chronic myelomonocytic leukemia. 2011 , 96, 375-83	186
520	Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. 2011 , 96, 441-9	180
519	Myelodysplastic syndromes. 2011 , 31, 763-84	6
518	Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. 2011 , 27, 951-60	26
517	Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?. 2011 , 11 Suppl 1, S46-8	4
516	Standard therapy for patients with myelodysplastic syndromes. 2011 , 11, 303-13	3
515	Physiology and pathology of nuclear phospholipase C β . 2011 , 51, 2-12	16
514	Le sindromi mielodisplastiche: diagnosi, prognosi e terapia. 2011 , 5, 90-97	1
513	5-Azacitidine in myelodysplastic syndromes: a clinical practice guideline. 2011 , 37, 160-7	23
512	The presence of -308A TNF β is associated with anemia and thrombocytopenia in patients with myelodysplastic syndromes. 2011 , 47, 255-8	6
511	[Myelodysplastic syndrome with erythroblastopenia]. 2011 , 32, 33-8	2
510	Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature. 2011 , 11, 293-7	6
509	Myelodysplastic syndromes. 2011 , 28, 258-72	11
508	The epidemiology of myelodysplastic syndromes (MDS) and myeloproliferatif/myelodysplastic diseases (MDS/MPS). 2011 , 17, 124-131	
507	Myelodysplastic syndromes. 2011 , 303-320	
506	Classification of Acute Leukemia. 2011 ,	4
505	The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. 2011 , 43, 536-46	8

504	p15INK4b, a Tumor Suppressor in Acute Myeloid Leukemia. 2011,		
503	Myelodysplastic syndrome of del 20q with plasma cell dysplasia. 2011, 51, 141-5		
502	NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. 2011, 9, 30-56		140
501	Mitral valve repair in a patient with myelodysplastic syndrome. 2011, 17, 614-7		3
500	Myelodysplastic syndrome: classification and changing concept. 2011, 1, 142-150		
499	Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). 2011, 96, 1433-40		192
498	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. 2011, 118, 3765-76		348
497	T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. 2011, 117, 2691-9		64
496	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. 2011, 118, 4690-3		68
495	A case of chronic myelomonocytic leukemia who developed pericardial effusion during stably controlled leukocytosis. <i>Internal Medicine</i> , 2011, 50, 1737-40		1.1
494	Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. 2011, 96, 349-52		17
493	Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: improved outcomes for de novo disease. 2011, 15, 334-43		10
492	Myelodysplasia in the Wellington region 2002-2007: disease incidence and treatment patterns. 2011, 41, 399-407		4
491	Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. 2011, 102, 1680-6		29
490	Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. <i>British Journal of Haematology</i> , 2011, 152, 89-98	4.5	27
489	Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 153, 149-67	4.5	45
488	Advances in the prognostication and management of advanced MDS in children. <i>British Journal of Haematology</i> , 2011, 154, 185-95	4.5	45
487	Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. <i>British Journal of Haematology</i> , 2011, 155, 599-606	4.5	86

486	Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. 2011 , 25, 110-20	98
485	Synergistic induction of PI-PLC β signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. 2011 , 25, 271-80	35
484	Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. 2011 , 25, 387-99	56
483	Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. 2011 , 25, 1147-52	369
482	Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. 2011 , 1242, 40-55	146
481	Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts. 2011 , 86, 512-6	2
480	Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of \geq 20 g/L with darbepoetin alfa + filgrastim or erythrocyte transfusions. 2011 , 87, 244-52	47
479	Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. 2011 , 35, 1591-6	136
478	Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. 2012 , 36, 1-5	68
477	Classification and prognostic evaluation of myelodysplastic syndromes. 2011 , 38, 627-34	55
476	Computerized texture analysis of atypical immature myeloid precursors in patients with myelodysplastic syndromes: an entity between blasts and promyelocytes. 2011 , 6, 93	10
475	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. 2011 , 118, 3932-41	265
474	Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. 2011 , 22, 623-9	9
473	Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. 2011 , 90, 655-66	10
472	Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome. 2011 , 94, 169-177	13
471	Azacitidine for the treatment of myelodysplastic syndromes in the elderly. 2011 , 28 Suppl 2, 10-5	1
470	Treatment of myelodysplastic syndromes in elderly patients. 2011 , 28 Suppl 2, 1-9	1
469	Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia. 2011 , 28 Suppl 3, 1-9	5

468	Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. 2011 , 2, 389-99		36
467	Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder. 2011 , 17, 834-9		17
466	The search for better prognostic models in myelodysplastic syndromes. 2011 , 6, 13-21		9
465	Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions. 2011 , 6, 5-12		3
464	Management of lower-risk myelodysplastic syndromes: the art and evidence. 2011 , 6, 145-53		22
463	Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. 2011 , 4, 19		34
462	The physiology and pathology of inositide signaling in the nucleus. 2011 , 226, 14-20		26
461	Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. <i>American Journal of Hematology</i> , 2011 , 86, 163-9	7.1	31
460	Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. <i>American Journal of Hematology</i> , 2011 , 86, 540-5	7.1	26
459	Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. 2011 , 63, 1188-94		61
458	A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 2011 , 117, 1253-61		26
457	Activity of azacitidine in chronic myelomonocytic leukemia. 2011 , 117, 2690-6		108
456	Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. 2011 , 117, 2697-702		139
455	Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. 2011 , 117, 5529-37		41
454	Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. 2011 , 78, 150-61		9
453	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. 2011 , 35, 159-62		33
452	Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia. 2011 , 35, 516-21		12
451	Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. 2011 , 35, 479-83		7

450	The Myelodysplastic Syndromes (MDS) Foundation: a retrospective analysis of a nonprofit foundation. 2011 , 35, 283-5	1
449	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. 2011 , 35, 863-7	34
448	Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. 2011 , 35, 868-73	49
447	Epigenetic regulation in myelodysplastic syndromes: implications for therapy. 2011 , 20, 465-93	16
446	Antiangiogenesis in myelodysplastic syndrome. 2011 , 11, 1044-52	5
445	Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. 2011 , 29, 428-34	82
444	Myelodysplastic/myeloproliferative neoplasms. 2011 , 391-406	
443	Cytogenetic abnormalities in myelodysplastic syndrome: an overview. 2011 , 16, 131-8	22
442	Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload--the RELATH study. 2011 , 16, 265-73	9
441	The Myelodysplastic Syndromes. 2011 ,	
440	Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?. 2011 , 2011, 214143	16
439	Prognostic relevance of cytogenetic systems in myelodysplastic syndromes. 2012 , 53, 1640-2	1
438	Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. 2012 , 104, 1724-37	123
437	Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study. 2012 , 53, 940-6	13
436	Twenty Years of G-CSF. 2012 ,	6
435	How to manage lower-risk myelodysplastic syndromes. 2012 , 26, 390-4	5
434	Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. 2012 , 26, 2474-82	29
433	C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. 2012 , 26, 303-11	32

432	Nuclear PI-PLC β and myelodysplastic syndromes: genetics and epigenetics. 2012 , 18, 1751-4	8
431	Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. 2012 , 36, 1302-16	68
430	Diagnosis and classification. 21-48	1
429	Myelodysplastic syndrome. 429-443	
428	Chronic myeloproliferative disorders. 444-502	3
427	Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy. 2012 , 41, 611-4	7
426	Recurrent acute lower-limb ischemia with multiple organ infarctions secondary to acute myeloid leukaemia M1. 2012 , 26, 1128.e1-5	3
425	Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. 2012 , 26, 2447-54	82
424	Revised international prognostic scoring system for myelodysplastic syndromes. 2012 , 120, 2454-65	1799
423	Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. 2012 , 125, S6-13	38
422	Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction. 2012 , 125, S26-30	7
421	Erythroid proliferations in myeloid neoplasms. 2012 , 43, 153-64	23
420	Myelodysplastic syndrome in New Zealand and Australia. 2012 , 42, 1235-42	12
419	Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. 2012 , 72, 1111-36	29
418	Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?. 2012 , 5, 17-26	13
417	Targeting acute myeloid leukemia cells with cytokines. 2012 , 92, 567-75	9
416	Overview of myelodysplastic syndromes. 2012 , 49, 287-94	6
415	Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. 2012 , 49, 330-41	31

414	Introduction: application of new therapies to myelodysplastic syndrome. 2012 , 49, 285-6	
413	Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission. 2012 , 12, 444-51	7
412	Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. 2012 , 36, 1093-7	21
411	Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. 2012 , 36, 1380-6	30
410	Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. 2012 , 36, 1376-9	11
409	Prognostic scoring systems in MDS. 2012 , 36, 1463-9	19
408	Historical perspectives on myelodysplastic syndromes. 2012 , 36, 1441-52	8
407	The classification of MDS: from FAB to WHO and beyond. 2012 , 36, 1453-8	35
406	Molecular genetics in myelodysplastic syndromes. 2012 , 36, 1459-62	22
405	[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations]. 2012 , 138, 119.e1-9	1
404	Update on the science of myelodysplastic syndromes. 2012 , 16 Suppl, 9-22	2
403	Myelodysplastic Disorders. 2012 , 331-344	
402	Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. 2012 , 7, 310-20	63
401	Phosphoinositides and Disease. 2012 ,	1
400	Prognostic features of patients with myelodysplastic syndromes aged 2012, 53, 2439-43	6
399	The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. 2012 , 91, 1333-43	33
398	Pregnancy complicated with myelodysplastic syndrome and severe preeclampsia: A case report. 2012 , 55, 745	
397	Epigenetics in Cancer: The Myelodysplastic Syndrome as a Model to Study Epigenetic Alterations as Diagnostic and Prognostic Biomarkers. 2012 ,	

396	Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience. <i>Hematological Oncology</i> , 2012 , 30, 76-81	1.3	20
395	Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012 , 87, 610-9	7.1	37
394	Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. 2012 , 118, 4462-70		35
393	Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. 2012 , 118, 4806-14		54
392	Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2012 , 82, 295-304	3.4	12
391	Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. 2012 , 95, 232-8		26
390	Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island. 2012 , 95, 420-7		1
389	Angiogenesis and survival in patients with myelodysplastic syndrome. 2012 , 18, 681-90		15
388	Characteristics of MDS patients seen at private practices differ significantly from those treated at university hospitals in Germany. 2012 , 138, 953-7		2
387	Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. 2012 , 36, 132-9		13
386	The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. 2012 , 36, 448-52		22
385	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. 2012 , 36, 287-92		16
384	The quest for the perfect MDS scoring system. 2012 , 36, 125-6		1
383	Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study. 2012 , 36, 575-80		1
382	Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. 2012 , 36, 727-34		53
381	Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. <i>British Journal of Haematology</i> , 2012 , 158, 232-237	4.5	11
380	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. 2012 , 118, 127-33		36
379	Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. 2012 , 91, 39-46		8

378	Microscopic examination of bone marrow aspirates in malignant disorders of haematopoiesis--a comparison of two slide preparation techniques. 2012 , 91, 497-505		4
377	Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. 2013 , 6, 29		45
376	Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. 2013 , 92, 19-24		46
375	Development and validation of QOL-E [®] instrument for the assessment of health-related quality of life in myelodysplastic syndromes. 2013 , 8, 835-844		2
374	Border between aplastic anemia and myelodysplastic syndrome. 2013 , 97, 558-63		8
373	Myelodysplastic syndromes: what do hospitalists need to know?. 2013 , 8, 351-7		18
372	Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines. 2013 , 41, 189-97		21
371	Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with 2013, 13, 144-52		15
370	High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. 2013 , 92, 621-31		34
369	Myelodysplastic Syndromes. 2013 ,		
368	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013 , 88, 581-8	7.1	46
367	Therapeutic effects of thalidomide in hematologic disorders: a review. 2013 , 7, 290-300		9
366	Myelodysplastic syndromes: toward a risk-adapted treatment approach. 2013 , 6, 611-24		21
365	Current therapy of myelodysplastic syndromes. 2013 , 27, 243-59		69
364	Monosomal karyotype in MDS: explaining the poor prognosis?. 2013 , 27, 1988-95		38
363	Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. 2013 , 27, 879-88		39
362	Standardizing the initial evaluation for myelodysplastic syndromes. 2013 , 8, 361-9		4
361	Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome. 2013 , 62, 1830-9		28

360	Morphology, cytogenetics and classification of MDS. 2013 , 26, 337-53		31
359	Myelodysplastic syndromes should be renamed as myelodysplastic neoplasms. 2013 , 37, 463-4		1
358	Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013 , 88, 967-74	7.1	22
357	Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. 2013 , 54, 1450-8		20
356	Abstracts of the Lectures During Haematocon 2013. 2013 , 29, 191-277		1
355	Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes. 2013 , 98, 687-93		4
354	There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. 2013 , 8, 351-60		31
353	Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). 2013 , 37, 637-40		40
352	Prognostic factors and risk models in myelodysplastic syndromes. 2013 , 13 Suppl 2, S295-9		12
351	Current pathology practices in and barriers to MDS diagnosis. 2013 , 37, 1656-61		10
350	The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. 2013 , 85, 162-92		8
349	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?. 2013 , 37, 416-21		13
348	High frequency of NAD(P)H:quinone oxidoreductase 1 (NQO1) C(609)T germline polymorphism in MDS/AML with trisomy 8. 2013 , 37, 742-6		5
347	Update on Myelodysplastic Syndromes Classification and Prognosis. 2013 , 6, 693-728		1
346	Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study. 2013 , 37, 862-7		10
345	The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?. 2013 , 6, 59-68		13
344	Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. 2013 , 26, 751-61		32
343	Myelodysplasia: new approaches. 2013 , 14, 156-69		4

342	Pathology of the Chronic Myeloid Leukemias. 2013 , 19-28		
341	Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2013 , 161, 339-47	4.5	67
340	Pathophysiology of Acute Lymphoblastic Leukemia. 2013 ,		0
339	[Myelodysplastic syndromes]. 2013 , 54, 699-708		
338	Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome. 2013 , 37, 71-5		17
337	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. <i>British Journal of Haematology</i> , 2013 , 162, 74-86	4.5	59
336	Refractory anemia with ring sideroblasts. 2013 , 26, 377-85		30
335	Surgical treatment for esophageal cancer patients with myelodysplastic syndrome. 2013 , 10, 149-152		1
334	Histopathological and immunohistochemical evaluation of bone marrow biopsy in myelodysplastic syndromes. 2013 , 2, 219-228		
333	Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. 2013 , 98, 201-7		30
332	Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. 2013 , 5, e2013032		3
331	Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the FAB classification. 2013 , 140, 253-7		
330	Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. 2013 , 31, 2662-70		203
329	Epidemiology and risk factors for infections in myelodysplastic syndromes. 2013 , 15, 652-7		13
328	Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients. 2013 , 59, 152-8		4
327	Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. 2013 , 52, 1167-77		28
326	The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany. 2013 , 91, 473-82		15
325	Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013 , 88, 365-9	7.1	22

324	Proposed score for survival of patients with myelodysplastic syndromes. 2013 , 43, 1120-8	10
323	Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. 2013 , 98, 1344-52	33
322	Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. 2013 , 27, 1283-90	54
321	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). 2013 , 122, 1974-82	69
320	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. 2013 , 121, 3005-15	197
319	Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. 2013 , 122, 4279-86	142
318	Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?. 2013 , 98, 490-1	12
317	Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. 2013 , 98, 568-75	52
316	Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society. 2013 , 68, 253-62	2
315	Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. 2013 , 98, 584-90	12
314	The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features. 2013 , 11, 877-84; quiz 885	26
313	A case of myelodysplastic syndrome with marked eosinophilia showing favorable prognosis. 2013 , 48, 222-5	1
312	The myelodysplastic syndromes: diagnosis, prognosis and therapy. 2013 , 90-97	
311	Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. 2013 , 109, 909-19	11
310	A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes. 2013 , 8, e67537	24
309	Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. 2013 , 8, e81048	20
308	Acute myelogenous leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: retrospective analysis of molecular genetic evaluation. 2014 , 27, 299-304	1
307	MicroRNA dysregulation in the myelodysplastic syndromes. 2014 , 2, 174-86	2

306	. 2014,	1
305	. 2014,	7
304	Stopping higher-risk myelodysplastic syndrome in its tracks. 2014 , 9, 421-31	2
303	Translational hematology. 2014 , 164, 487-96	
302	Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan. 2014 , 100, 478-84	6
301	Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML. 2014 , 20, 3589-602	19
300	Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. 2014 , 7, 74	60
299	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. 2014 , 28, 621-8	68
298	Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). 2014 , 4, e242	19
297	Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome. 2014 , 2014, 542395	7
296	Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. 2015 , 6, 1-16	12
295	+ 252A/G polymorphism in lymphotoxin- β gene influences long-term survival in patients with myelodysplastic syndrome with excess blasts. 2014 , 55, 1406-7	1
294	Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. 2014 , 55, 2901-6	8
293	Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia. <i>British Journal of Haematology</i> , 2014 , 166, 720-8	4.5 6
292	De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with \geq 30% blasts in older adults: a Bone Marrow Pathology Group study. <i>American Journal of Hematology</i> , 2014 , 89, E193-9	7.1 17
291	IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. <i>American Journal of Hematology</i> , 2014 , 89, E142-9	7.1 14
290	Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. 2014 , 38, 1413-9	60
289	BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. <i>American Journal of Hematology</i> , 2014 , 89, 499-504	7.1 28

288	IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. <i>American Journal of Hematology</i> , 2014 , 89, 137-44	7.1	68
287	Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. 2014 , 92, 137-46		10
286	Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2014 , 89, 509-16	7.1	22
285	Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. <i>American Journal of Hematology</i> , 2014 , 89, 181-6	7.1	49
284	Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. 2014 , 93, 429-38		23
283	Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome. 2014 , 52, 1859-65		3
282	Lessons from the atomic bomb about secondary MDS. 2014 , 9, 407-11		1
281	Results of treatment with azacitidine in patients aged ≥75 years included in the Spanish Registry of Myelodysplastic Syndromes. 2014 , 55, 1300-3		15
280	Myelodysplastic syndromes in the United States: an update for clinicians. 2014 , 46, 283-9		19
279	The Myelodysplastic Syndromes. 2014 , 42-48		
278	Current and novel therapeutic approaches in myelodysplastic syndromes. 2014 , 12, 236-49		3
277	Dysplasia features of myelodysplastic syndrome in ethnically Chinese people. 2014 , 131, 126-32		4
276	Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool. 2014 , 5, e0025		
275	Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. 2014 , 106, djt462		17
274	Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes. 2014 , 131, 231-8		14
273	Initially lymphocytic Sweet's syndrome in male patients with myelodysplasia: a distinguished clinicopathological entity? Case report and systematic review of the literature. 2014 , 132, 220-5		9
272	Disseminated noninterstitial granulomatous dermatitis as a cutaneous manifestation of the preleukemic state in a patient with myelodysplasia and ulcerative colitis--apropos a case and review of the literature. 2014 , 36, e117-20		6
271	Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. 2014 , 38, 57-64		50

270	Receptors, cells and circuits involved in pruritus of systemic disorders. 2014 , 1842, 869-92		62
269	Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). 2014 , 9, 57-65		11
268	Guidelines for the diagnosis and management of adult myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014 , 164, 503-25	4-5	69
267	Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. 2014 , 38, 447-53		34
266	Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014 , 165, 49-56	4-5	7
265	Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. 2014 , 93, 57-64		13
264	Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. 2014 , 50, 1004-12		39
263	Small Molecules in Oncology. 2014 ,		3
262	Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. 2014 , 50, 3198-205		24
261	Myelodysplastic/Myeloproliferative Neoplasms. 2014 , 511-552		
260	Myelodysplastic Syndromes. 2014 , 181-284		
259	Acute Myeloid Leukaemia. 2014 , 285-421		1
258	High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014 , 167, 100-9	4-5	21
257	Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice. 2014 , 9, 301-10		2
256	Significance of telomere capture in myelodysplastic syndromes. 2014 , 31, 216		
255	The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. 2014 , 7, 61		27
254	Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. <i>British Journal of Haematology</i> , 2014 , 166, 189-201	4-5	12
253	Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. 2014 , 20, 425-9		12

252	Isolated clonal cytogenetic abnormalities after high-dose therapy. 2014 , 20, 1130-8		6
251	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. 2014 , 38, 258-62		5
250	Predicting response to epigenetic therapy. 2014 , 124, 47-55		56
249	Morphology of Blood Cells. 2014 , 67-185		1
248	The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. 2014 , 99, e31-2		24
247	Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. 2014 , 123, 3327-35		45
246	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. 2014 , 123, 2333-42		119
245	Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells. 2015 , 5, 16709		15
244	ST2: the biomarker at the heart of GVHD severity. 2015 , 125, 10-1		11
243	Genes break barrier between MDS and AML. 2015 , 125, 9-10		4
242	The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons. <i>Internal Medicine</i> , 2015 , 54, 445-51	1.1	5
241	[Late-onset lupus in the elderly after 65 years: retrospective study of 18 cases]. 2015 , 13, 157-68		1
240	Myelodysplastic syndromes in South America: a multinational study of 1080 patients. <i>American Journal of Hematology</i> , 2015 , 90, 851-8	7.1	7
239	Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. <i>British Journal of Haematology</i> , 2015 , 170, 372-83	4.5	47
238	Syndromes Affecting Periodontium. 2015 , 6, 1-10		
237	[Myelodysplastic syndromes: pathophysiology, clinical and biological features]. 2015 , 73, 643-56		0
236	Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation. 2015 , e398-412		8
235	Hematopoietic cell transplantation for myelodysplastic syndrome. 2015 , e375-80		6

234	Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study. 2015 , 94, e737	15
233	Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. 2015 , 15, e143-9	1
232	Hematopoietic stem cell transplantation in children with refractory cytopenia of childhood: single-center experience using high-dose cytarabine containing myeloablative and aplastic anemia oriented reduced-intensity conditioning regimens. 2015 , 21, 565-9	14
231	Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. 2015 , 106, 287-93	23
230	Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?. 2015 , 28, 14-21	6
229	Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes. 2015 , 21, 460-7	11
228	Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. 2015 , 94, 23-34	10
227	Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2015 , 88, 154-64	3-4 17
226	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. 2015 , 100, 400-8	41
225	Clonal origin and evolution of myelodysplastic syndrome analyzed by dysplastic morphology and fluorescence in situ hybridization. 2015 , 101, 58-66	1
224	Acute Myeloid Leukemia With Myelodysplasia-Related Changes. 2015 , 144, 29-43	37
223	Clinical Significance of Cytogenetics in Myelodysplastic Syndromes. 2015 , 39, 367-370	2
222	Myelodysplastic syndromes in Chernobyl clean-up workers. 2015 , 94, 1639-43	2
221	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. 2015 , 127, 12-5	1
220	Chronic myelomonocytic leukemia: Forefront of the field in 2015. 2015 , 95, 222-42	19
219	RETRACTED ARTICLE: 5-Azacitidine for treating acute myelogenous leukemia. 2015 , 3, 1197-1207	1
218	Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). 2015 , 94, 2003-13	19
217	Whole-exome sequencing enhances prognostic classification of myeloid malignancies. 2015 , 58, 104-113	9

216	Anemia as the Main Manifestation of Myelodysplastic Syndromes. 2015 , 52, 348-56	25
215	The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes. 2015 , 37, 252-8	3
214	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. 2015 , 95, 168-76	26
213	Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. 2015 , 94, 779-87	47
212	Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes. 2015 , 94, 519-25	1
211	The myelodysplastic syndromes: the era of understanding. 2015 , 94, 379-90	7
210	Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes. 2016 , 101, e177-81	6
209	Myelodysplastic Syndrome in Patients with Acute Radiation Syndrome Following the Chornobyl Nuclear Power Plant Accident. 2016 , 04,	
208	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. 2016 , 11, e0166245	5
207	Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. 2016 , 7, 32065-78	24
206	Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?. 2016 , 23, 167-74	13
205	Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016 , 174, 227-34	4.5 4
204	Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. 2016 , 97, 33-8	21
203	Chronic myelomonocytic leukemia [myelodysplastic type] transformation to acute myeloid leukemia [diagnostic and therapeutic options: case report and literature review / Leucemie mielomonocitar [cronic] forma mielodisplazic [transformare spre leucemie acut [mieloid]] diagnostic [opțiuni terapeutice: prezentare de caz [revizuirea literaturii]. 2016 , 24, 263-277	
202	Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia. 2016 , 48, 233-41	5
201	Quality control initiative on the evaluation of the dysmegakaryopoiesis in myeloid neoplasms: Difficulties in the assessment of dysplasia. 2016 , 45, 75-81	21
200	Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study. 2016 , 45, 82-9	9
199	Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. 2016 , 30, 2055-2063	63

198	β-Hemoglobin-stabilizing Protein: An Effective Marker for Erythroid Precursors in Bone Marrow Biopsy Specimens. 2016 , 24, 51-6		6
197	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. 2016 , 127, 2890-902		69
196	PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. 2016 , 16 Suppl, S67-73		3
195	Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS). <i>British Journal of Haematology</i> , 2016 , 175, 917-924	4.5	6
194	Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia. 2016 , 554-565		
193	Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. 2016 , 613-627		
192	Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients. 2016 , 48, 57-61		5
191	Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016 , 91, 631-42	7.1	47
190	Abnormal neutrophil scattergram obtained using Pentra MS CRP in the patients with myelodysplastic syndrome showing dysgranulopoiesis. 2016 , 38, 27-33		7
189	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. 2016 , 29, 1541-1551		11
188	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. 2016 , 34, 3284-92		18
187	Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2016 , 175, 393-401	4.5	16
186	Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. 2016 , 104, 566-573		7
185	Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. <i>British Journal of Haematology</i> , 2016 , 174, 847-58	4.5	20
184	Good riddance to the term "refractory anemia" in myelodysplastic syndromes. 2016 , 51, 22-26		3
183	Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome. 2016 , 260, 176-185		10
182	Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki. 2016 , 107, 1484-1491		8
181	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. 2016 , 9, 39		28

180	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. 2016 , 101, e224-7		30
179	Could the mosaic pattern of chromosomal abnormality predict overall survival of patients with myelodysplastic syndrome?. 2016 , 9, 41-7		1
178	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. 2016 , 18, 4		14
177	Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. 2016 , 54, 49-56		25
176	Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine. 2016 , 57, 2709-11		2
175	Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 123-30	7.1	6
174	Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes. 2016 , 103, 227-33		3
173	SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis. 2016 , 44, 8-16		12
172	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. 2016 , 17, 496-508		112
171	Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis. 2016 , 154, 9-23		89
170	A method for determining both multiple refractive indices and 3D substructure of a binucleate cell. 2016 , 365, 113-119		3
169	The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system. 2016 , 30, 658-65		32
168	Hypermethylation of DLX4 predicts poor clinical outcome in patients with myelodysplastic syndrome. 2016 , 54, 865-71		8
167	Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). 2017 , 58, 298-307		9
166	New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. 2017 , 57, 78-84		18
165	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2017 , 92, 674-682	7.1	17
164	Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. 2017 , 106, 375-384		15
163	GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. 2017 , 6, 267-274		20

162	Diagnostic value of platelet indices and bone marrow megakaryocytic parameters in immune thrombocytopenic purpura. 2017 , 28, 83-90		19
161	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. 2017 , 30, 1213-1222		36
160	Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes. 2017 , 96, 1287-1295		2
159	Hematological Disorders in Children. 2017 ,		2
158	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. <i>American Journal of Hematology</i> , 2017 , 92, 599-606	7.1	32
157	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. 2017 , 123, 2661-2670		8
156	Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. 2017 , 99, 112-118		11
155	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). <i>American Journal of Hematology</i> , 2017 , 92, 614-621	7.1	8
154	The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. 2017 , 57, 102-103		
153	The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome. 2017 , 58, 1893-1902		6
152	TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2017 , 176, 600-608	4.5	45
151	Models of Prognostication in Chronic Myelomonocytic Leukemia. 2017 , 12, 513-521		6
150	Individual risk assessment in MDS in the era of genomic medicine. 2017 , 54, 133-140		2
149	Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives. 2017 , 91, 3717-3735		8
148	Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics. 2017 , 12, 448-454		3
147	Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan Public Health Centre-based Prospective Study. <i>British Journal of Haematology</i> , 2017 , 178, 747-755	4.5	11
146	JSH Guideline for Tumors of Hematopoietic and Lymphoid Tissues: Leukemia: 6. Myelodysplastic syndromes (MDS). 2017 , 106, 151-159		2
145	DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia. 2017 , 63, 62-71		19

144	Azacitidine in adult patients with acute myeloid leukemia. 2017 , 116, 159-177	31
143	Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). 2017 , 10, 131	4
142	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. 2017 , 23, 75-80	2
141	Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). 2017 , 58, 1686-1693	12
140	Cytogenetic profiling by FISH microscopy and comparison with light microscopy and complete blood count findings in myelodysplastic syndrome. 2017 , 265, 94-100	1
139	An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia. 2017 , 23, 3025-3034	17
138	3 Morphologie der Zellen im peripheren Blutaussstrich. 2017 , 94-263	
137	Diagnostics and Prognostication of Myelodysplastic Syndromes. 2017 , 37, 465-474	13
136	Erythrocyte and Leucocyte Cytochemistry. 2017 , 312-329	2
135	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. 2017 , 8, 73483-73500	99
134	Azacitidine Use for Myeloid Neoplasms. 2018 , 18, e147-e155	3
133	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018 , 93, 895-901	7.1 8
132	Inter-observer variance and the need for standardization in the morphological classification of myelodysplastic syndrome. 2018 , 69, 54-59	13
131	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. 2018 , 8, 39	43
130	Changing role of bone marrow examination in the diagnosis of hematological malignancies. 2018 , 59, 2018-2020	1
129	Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. 2018 , 67, 56-59	10
128	Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. 2018 , 14, 270-278	4
127	Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model. 2018 , 59, 2227-2232	2

126	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. 2018 , 11, 109-116	3
125	Dynamics of mutation and prognostic relevance in patients with primary myelodysplastic syndrome. 2018 , 10, 42	22
124	Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and CYP2D6*4 Polymorphism in the Etiology of Childhood Acute Leukemia. 2018 , 40, e207-e214	6
123	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. 2018 , 97, 1183-1191	11
122	Verification of Survival Predictors in Elderly Patients with Myelodysplastic Syndrome from Outpatient Clinical Practice. 2018 , 12, 27-31	0
121	Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases. <i>British Journal of Haematology</i> , 2018 , 180, 321-334	4.5 23
120	Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome. 2018 , 56, 485-491	2
119	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. 2018 , 59, 1121-1126	1
118	Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. 2018 , 24, 521-531	44
117	Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML. 2018 , 65, 1-4	13
116	Shanghai Health Study (2001-2009): What was learned about benzene health effects?. 2018 , 48, 217-251	20
115	Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?. 2018 , 64, 24-29	8
114	DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. 2018 , 13, 8-18	8
113	Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. 2018 , 23, 159-170	16
112	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. 2018 , 103, 69-79	21
111	Therapeutic Vulnerabilities in -Mutant AML Unmasked by Palbociclib. 2018 , 19,	7
110	Myelodysplastic Syndrome and Subsequent Diagnosis of Primary Solid Tumors: Evidence from the National Cancer Institute 2001-2011. 2018 , 38, 5819-5823	0
109	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. 2018 , 57, 547-556	0

108	Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. 2018 , 132, 2629-2638		50
107	Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2018 , 94, 901-909	3-4	5
106	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. 2018 , 13, 467-476		4
105	Incidence of Myelodysplastic Syndromes in a Major Canadian Metropolitan Area. 2018 , 3, 378-383		1
104	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. 2018 , 73, 51-57		13
103	Myelodysplastic Syndromes. 2018 , 539-563.e2		1
102	Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial. 2018 , 109, 3209-3215		9
101	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2018 , 93, 824-840	7-1	73
100	Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome. 2018 , 18, 469-474.e1		0
99	Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. <i>British Journal of Haematology</i> , 2018 , 182, 830-842	4-5	12
98	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. 2018 , 101, 502-507		4
97	Progress in the Classification of Hematopoietic and Lymphoid Neoplasms. 2018 , 763-773		
96	Myelodysplastic Syndromes. 2018 , 944-969.e13		0
95	Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment. 2018 , 8, 119		9
94	Minimally invasive mitral valve repair via right mini-thoracotomy in patient with myelodysplastic syndrome. 2018 , 13, 45		
93	More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. 2018 , 18, 4		5
92	Part 2: Myelodysplastic syndromes - classification systems. 2018 , 40, 262-266		0
91	Molecular Basis of Lymphoid and Myeloid Diseases. 2018 , 299-328		1

90	Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study. 2018 , 74, 137-143	5
89	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. 2019 , 86, 30-38	33
88	The current approach to the diagnosis of myelodysplastic syndromes. 2019 , 56, 15-21	9
87	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research. 2019 , 131, 410-418	9
86	Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. 2019 , 110, 533-542	4
85	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. 2019 ,	
84	Decitabine promotes apoptosis in mesenchymal stromal cells isolated from patients with myelodysplastic syndromes by inducing reactive oxygen species generation. 2019 , 863, 172676	4
83	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. 2019 , 94, 1467-1474	8
82	A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA. 2019 , 9, 13385	26
81	Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma. 2019 , 8,	23
80	Medical Conditions and Modifiable Risk Factors for Myelodysplastic Syndrome: A Systematic Review. 2019 , 28, 1502-1517	8
79	Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy. 2019 , 83, 106170	7
78	Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions. 2019 , 141, 54-72	12
77	EPO-R+ myelodysplastic cells with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells. 2019 , 78, 1-8	4
76	Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome. 2019 , 19, e367-e373	0
75	Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. 2019 , 8, 2188-2195	5
74	Diagnosis and Classification of Myelodysplastic Syndrome. 2019 ,	
73	ACUTE MYELOID LEUKAEMIA, MIXED PHENOTYPE ACUTE LEUKAEMIA, THE MYELODYSPLASTIC SYNDROMES AND HISTIOCYTIC NEOPLASMS. 2019 , 185-266	

72	MYELOPROLIFERATIVE AND MYELOYDYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS AND RELATED CONDITIONS. 2019 , 267-345		
71	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. 2019 , 98, 1367-1381		6
70	Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. 2019 , 54, 1471-1481		2
69	Mastering the multitude of monocytoses. 2019 , 104, 1912-1914		0
68	Molecular Genetics in Myelodysplasia Outcomes Prognostication. 2019 , 2, 35-43		
67	. 2019 ,		10
66	Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. 2019 , 14, 543-549		1
65	Myelodysplastic Syndromes (MDS). 2019 , 333-341		
64	Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. <i>Hematological Oncology</i> , 2019 , 37, 85-95 ¹³		4
63	Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study. 2019 , 60, 1136-1145		0
62	From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes. 2019 , 58, 474-483		5
61	Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. 2019 , 34, 1-15		60
60	A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. <i>British Journal of Haematology</i> , 2020 , 188, 404-412	4.5	6
59	Myelodysplastic syndromes. 2020 , 589-602		
58	Gaucher disease, myelodysplastic syndrome and ICUS. 2020 , 80, 102373		3
57	The evolving role of next generation sequencing in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2020 , 188, 224-239	4.5	7
56	Myelodysplastic Syndromes. 2020 , 1798-1820.e11		
55	Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?. 2020 , 33, 101132		3

54	Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?. 2020 , 33, 101139		1
53	How I investigate chronic myelomonocytic leukemia. 2020 , 42, 101-108		6
52	Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2020 , 95, 97-115	7.1	54
51	Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia. <i>British Journal of Haematology</i> , 2020 , 188, 796-800	4.5	1
50	No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki. 2020 , 111, 4490-4499		1
49	Serum Inflammation-miR Signature: A Biomarker of Myelodysplastic Syndrome?. 2020 , 10, 595838		1
48	Identification of latent core genes and pathways associated with myelodysplastic syndromes based on integrated bioinformatics analysis. 2020 , 25, 299-308		4
47	Prognostic Markers of Myelodysplastic Syndromes. 2020 , 56,		4
46	Diagnosis and Management of Myelodysplastic Syndromes. 2020 ,		
45	Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation. 2020 , 26, 6483-6493		3
44	Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome. 2020 , 112, 825-834		1
43	How I Diagnose Low-Grade Myelodysplastic Syndromes. 2020 , 154, 5-14		3
42	Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. 2020 , 61, 1688-1694		1
41	Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine. <i>British Journal of Haematology</i> , 2020 , 189, e144-e147	4.5	1
40	TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. 2020 , 30, 2776-2790.e6		11
39	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. 2020 , 153, 656-663		6
38	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients. 2020 , 21,		8
37	The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome. 2020 , 21,		3

36	Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold. 2020 , 60, 879-881		2
35	Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations. 2020 , 73, 728-736		3
34	The Blood Circulating Rare Cell Population. What is it and What is it Good For?. 2020 , 9,		13
33	Characterization of myelodysplastic syndromes progressing to acute lymphoblastic leukemia. 2021 , 100, 63-78		1
32	Autophagy in Hematological Malignancies: Molecular Aspects in Leukemia and Lymphoma. 2021 , 52, 16-23		0
31	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. 2021 , 35, 835-849		20
30	Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes. <i>Cytometry Part B - Clinical Cytometry</i> , 2021 , 100, 299-311	3-4	3
29	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. 2021 , 107, 265-274		2
28	Physician Education. 1996 , 1, 284-287		9
27	The Myelodysplastic Syndromes. 1997 , 2, 28-39		3
26	Understanding the Myelodysplastic Syndromes. 1997 , 2, 389-401		32
25	Five cases of Pyoderma Gangrenosum.. 1995 , 57, 709-720		3
24	Prediction of progression from refractory cytopenia with unilineage dysplasia by analysis of bone marrow blast cell composition. 2012 , 52, 63-6		3
23	Low-dose cytarabine in acute myeloid leukaemia. 1984 , 141, 643-6		8
22	CLINICOPATHOLOGICAL FEATURES OF NIGERIANS WITH MYELODYSPLASTIC SYNDROMES. 2006 , 3,		
21	A Case Of Anemia and Thrombocytopenia with Myelodysplastic Syndrome Successfully Treated with Juzentaihoto and Malt Sugar. 2011 , 62, 363-368		2
20	Myelodysplastic Syndromes. 99-114		
19	Myelodysplastic Syndromes: The Role of Cytogenetic and Molecular Abnormalities for Classification and Risk Assignment. 87-98		

18 Supportive Care in Myelodysplastic Syndrome. 172-190

17 A Case of Cutaneous Cryptococcosis. Report of a Case and Review of the Japanese Literature.. **1994**, 56, 20-26 2

16 A Painful Elevated Erythema (Neutrophilic Dermatitis) Associated with Myelofibrosis.. **1998**, 60, 603-607

15 Pediatric myelodysplastic syndrome. **2018**, 5, 23-35 2

14 Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation.. **2022**, 0

13 Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.. *American Journal of Hematology*, **2022**, 7.1 4

12 A Rare Case of Ankylosing Spondylitis Coexisting with Relapsing Polychondritis, Antiphospholipid Syndrome, and Myelodysplastic Syndrome.. *Internal Medicine*, **2022**, 1.1

11 Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.. *American Journal of Hematology*, **2022**, 7.1 3

10 Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis.. *Hematological Oncology*, **2022**, 1.3 0

9 Clinical, immunophenotypic, and cytogenetic characteristics of high-grade myelodysplastic syndromes with CD41-positive progenitor cells.. *Cytometry Part B - Clinical Cytometry*, **2021**, 3.4

8 Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes.. *British Journal of Haematology*, **2022**, 4.5

7 Somatic mutations in SF3B1 aberrant-negative MDS-RS most commonly involved in TP53 genes.. *Journal of Cellular and Molecular Medicine*, **2022**, 5.6

6 Somatic mutations of activating signalling, transcription factor, and tumour suppressor are a precondition for leukaemia transformation in myelodysplastic syndromes. 0

5 Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group. 1

4 Flow cytometry in the diagnosis of myelodysplastic syndromes. 0

3 The effects of mean platelet volume and red cell distribution width on prognosis in patients with myelodysplastic syndrome. 59-64 0

2 Myelodysplastic syndromes, thy name is heterogeneity. 0

1 Chronic myeloid leukemia presenting with absence of basophils and marked dyspoiesis. **2003**, 40, 144 0

